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ABSTRACT
Integrated Machine Learning and Bioinformatics Approaches for Prediction of Cancer-Driving
Gene Mutations
by Oluyemi Odeyemi
Cancer arises from the accumulation of somatic mutations and genetic alterations in cell division
checkpoints and apoptosis, this often leads to abnormal tumor proliferation. Proper classification
of cancer-linked driver mutations will considerably help our understanding of the molecular
dynamics of cancer. In this study, we compared several cancer-specific predictive models for
prediction of driver mutations in cancer-linked genes that were validated on canonical data sets
of functionally validated mutations and applied to a raw cancer genomics data.
By analyzing pathogenicity prediction and conservation scores, we have shown that evolutionary
conservation scores play a pivotal role in the classification of cancer drivers and were the most
informative features in the driver mutation classification. Through extensive comparative
analysis with structure-functional experiments and multicenter mutational calling data from PanCancer Atlas studies, we have demonstrated the robustness of our models and addressed the
validity of computational predictions. We evaluated the performance of our models using the
standard diagnostic metrics such as sensitivity, specificity, area under the curve and F-measure.
To address the interpretability of cancer-specific classification models and obtain novel insights
about molecular signatures of driver mutations, we have complemented machine learning
predictions with structure-functional analysis of cancer driver mutations in several key tumor
suppressor genes and oncogenes. Through the experiments carried out in this study, we found
that evolutionary-based features have the strongest signal in the machine learning classification
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of driver mutations and provide orthogonal information to the ensembled-based scores that are
prominent in the ranking of feature importance.
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1 General Introduction
1.1

Genetic Variation
Cancer is driven by changes at the cellular and molecular levels. Cancer development

and proliferation are associated with the accumulation of mutations. Notably, quite a few of
identified mutations are responsible for cellular variations leading to cancer. Most variations are
neutral and benign (passenger) in nature while a small fraction of the mutations drive the cancer
development process. Genetic variation describes the mutation in the genome’s DNA sequence.
Genetic variation is responsible for the distinct traits’ humans exhibit. It is the result of subtle
differences in the DNA. Variation occurs in germ and somatic cells. The only variation that
arises in germ cells can be inherited from one individual to another and so affect the dynamics of
the population, consequently leading to evolutionary changes. Mutation is the primary source of
genetic variation, however sexual reproduction and recombination contribute significantly to
genetic variation. A mutation is an alteration in the genome sequence. New mutations occur
when there are errors during DNA replication that are not corrected by DNA repair enzymes.
Mutation can be neutral, beneficial or damaging to an organism. Most somatic mutations are
salient but can occasionally interfere with major cellular functions. Accumulation of genetic
alteration can result in tumor development in oncogenes, tumor-suppressor genes and stability
genes (Vogelstein and Kinzler 2004; Vogelstein et al., 2013; Feinberg et al. 2006). Early somatic
mutation can lead to developmental disorders whereas incessant accumulation of mutation can
cause cancer. Human cells innately have several safety protocols to protect themselves against
the lethal effects of mutation inducing cancers. Therefore, it is the defective genes that result in
cancer proliferation (Yeang et al., 2008; Li et al., 2016).
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Genetic variations are generally divided into three main classes namely, single base-pair
substitution, insertion or deletion(indel) and structural variation. Single base-pair substitution is a
type of mutation in which a single nucleotide base is deleted or inserted from a DNA sequence
such as in transition (interchange of purine or pyrimidine nucleic acids) and transversion
(interchange of a purine and pyrimidine nucleic acids). Single nucleotide polymorphisms (SNPs)
result from the substitution of a single base-pair. (SNPs) are the most occurring type of genetic
variation in people. A SNP represents a difference in a single DNA base, and they are found
approximately in 1 out of every 300 bases. An example of SNPs would be a substitution of a
thymine nucleic acid with guanine.
Indel variation refers to the insertion and/or deletion of nucleotides in genomic DNA.
Indels play a significant role in the identification and detection of human diseases such as cancer.
Indels are a common kinase activation system in cancer (Sehn, 2015; Porter et al., 2015; Sanders
and Mason 2016). Indels are among the most common types of structural variants. Cumulatively,
there are between 1.5 and 2.7 million indel polymorphisms in the human population, with ~ 0.4
million short indels in each individual (McMahon et al., 2017). When an indel occurs within the
coding region of the DNA, it is referred to as ‘in-frame” and if the number of DNA lost or gained
is divisible by 3, it is referred to as frameshift because the triplet reading code is altered for all
subsequent nucleotides. Frameshift indels often lead to premature stop codons and most times
have more functional impact than in-frame indels (Sanders and Mason, 2016; Copley, 2010).
Yang et al., 2010 found a strong correlation between indels and base substitutions in cancerrelated genes and showed that they tend to concentrate at the same locus in the coding sequences
with the same samples. Also, they observed that a high proportion of indels are found in somatic
variation when compared with meiotic mutations. Yang et al. 2010 also concluded that indels can
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often be the driver-mutation in cancer proliferation that they attributed to the major influence of
indels on gene function.
Structural variation is the large-scale differences in the genomic DNA. They are the
region of DNA with base size larger than 1 kb. This genetic variation includes copy number
variants (CNVs) and chromosomal rearrangement events such as duplications, inversions,
translocation, deletions, and insertions. Identification of structural variation is crucial to genome
interpretation but has been historically challenging due to limitations inherent to available
genome technologies. Structural variations are mainly responsible for the evolutionary diversity
of human genomes at individual and population levels (Dennis and Eichler, 2016; Kosugi et al.,
2019). Pang et al., 2010 and Alkan et al., 2011 observed that the genomic difference between
individuals caused by structural variations has been estimated to be more than 3 times higher
than those by SNVs. Therefore, structural variations may have higher impacts on gene functions
than SNVs and short indels. Consequently, structural variations are affiliated
with human diseases such as cancer (Stankiewicz and Lupski, 2010).
1.2

Cancer-Linked Driver Mutation
Genomic instability is central to cancer development (McFarland et al., 2017; Burrell et

al., 2013). Genomic instability is responsible for driver and passenger mutations. Driver
mutations are responsible for driving carcinogenic processes. Whereas, passenger mutations have
no proliferative impact on cellular systems. Studies have shown that from sequenced cancers
passenger mutation accounts for over 90% of all genomic variation. The role of passenger
mutations is not clearly understood, with some studies arguing that passengers are misclassified
‘mini-drivers’ or effectively neutral and potentially harmful to cancer (Castro-Giner et al.,2015
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and McFarland et al., 2013). McFarland et al., 2017 observed that accumulated passenger
mutations can be moderately harmful to cancer cells. They further observed that although
passenger mutations exhibit individually weak effects on cancer progression, their collective
impact is in line with a skewed high number of driver mutations, leading to strife between
passengers and drivers. Consequently, passenger’s damaging effects are most evident in higher
mutation rates (McFarland et al., 2017).
The identification of driver mutations in cancer remains a challenging task. There are
several computational strategies aimed at detecting driver genes and ranking mutations for their
carcinogenicity prospect (Torkamani et al., 2009). Consequently, several driver genes are not
tagged as disease-related (Brown et al., 2019).
Presently, the reoccurrence of a mutation in patients remains one of the top reliable markers of
mutation driver status. Nonetheless, some mutations are more likely to occur than others due to
differences in background mutations rates arising from different types of DNA replication and
repair systems (Brown et al., 2019). From the study of Brown et al., 2019, they showed that
mutations not yet observed in a tumor had relatively low mutability, thus indicating that
background mutability might limit the occurrence of mutation. Also, they concluded that
mutability of driver mutations is often lower than that of passenger mutation and consequently
adjusting mutation recurrence frequency by mutability significantly improved prediction of
driver mutation.
1.3

Functional Prediction and Conservation Scores
Many algorithms have been designed to predict the molecular impact of amino acid

substitutions on protein function and measure the conservation of nucleotide positions. These
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algorithms map functional predictions and annotations for human splice site variants and nonsynonymous single-nucleotide variants thereby providing key supporting evidence to clinicians
when interpreting variants per the American College Medical Genetics (ACMG) guidelines. The
most common functional prediction algorithms are MetaSVM, MetaLR, CADD, PolyPhen2,
VEST3, PROVEAN, MutationTaster, MutationAssessor, FATHMM, and SIFT while the most
popular conservation score metrics are PhyloP, LRT and GERP2.
1.4

Machine Learning
Machine learning (ML) is a branch of artificial intelligence based on the concept that

systems can learn from data through pattern recognition. In recent years, machine learning has
been used to develop predictive models for a more robust understanding of biological systems. A
typical machine learning task consists of the following: 1) Exploratory data analysis, 2) Data
preprocessing, 3) Model training, 4) Feature optimization and model parameterization and 5)
Final predictions (Kandoi, 2019). Exploratory data analysis (EDA) and data preprocessing are
pivotal to any ML task. These steps involve data cleaning steps- handling missing values,
removal of redundant features, feature extraction, identification of predictors and target
variables. The accuracy of a machine learning model is dependent on its predictors’ capability of
distinguishing one class from another.
ML is broadly classified into supervised (classification and regression) and unsupervised
learning. Classification tasks have a categorical target variable, for example, gram-positive vs
gram-negative microorganisms while regression has continuous target variables such as a
colony-forming unit of Staphylococcus aureus. Unsupervised learning involves tasks without
pre-defined target variables such as dimension reduction and clustering.
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Some popular algorithms used for classification, regression, and unsupervised learning tasks
include ensemble tree-based algorithms, support vector machines, generalized linear regression,
general linear regression, k-means and self-organizing maps (Kandoi, 2019). Machine learning
plays a cardinal role in computational biology and bioinformatics. Drug target identification,
protein structure prediction, microbial morphology, gene function predictions are some of the
common applications of ML (Pierre and Soren, 2003; Yang 2010; Mitra 2019).
In this study we used machine learning models to: (i) identify and characterize cancer driving
mutations (SNVs) using functional, evolutionary-conservation and ensemble-score predictors,
(ii) reclassify genomic variants of unknown significance associated with cancer development
and (iii) classify survival status of unresectable cancers based on clinical and genomic features
1.5

Dissertation Organization

This dissertation is divided into six chapters. A summary of each chapter is given below.
Chapter 1 provides a background introduction to this dissertation.
Chapter 2 includes a published article motivating the need to study structure-functional analysis
of cancer-driving mutation in oncogenes and tumor suppressor genes. By examining sequence,
structure and ensembled-based features we were able to show that evolutionary conservation
scores play a critical role in the classification of cancer drivers thereby providing the strongest
signal in machine learning prediction. The article has been published under the title, “Machine
Learning Classification and Structure-Functional Analysis of Cancer Mutations Reveal Unique
Dynamic and Network Signatures of Driver Sites in Oncogenes and Tumor Suppressor Genes ”
by Agajanian S, Odeyemi O, Bischoff N, Ratra S, Verkhivker GM in the Journal of Chemical
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Information and modeling 2018 Oct 22;58(10):2131-2150. doi: 10.1021/acs.jcim.8b00414. Epub
2018 Oct 3.
Chapter 3 includes parts of an article “Integration of Random Forest Classifiers and Deep
Convolutional Neural Networks for Classification and Biomolecular Modeling of Cancer Driver
Mutations” by Steve Agajanian, Odeyemi Oluyemi, and Gennady Verkhivker published in
Frontiers in Molecular Biosciences 2019; 6: 44. By analyzing raw nucleotide sequences for
cancer driver mutation classification, we integrated various ensemble-based approaches with
deep convolutional neural networks to predict cancer driver mutation in genomic datasets.
Chapter 4 includes a manuscript currently under preparation or submission to a peer-reviewed
paper. In the paper titled “Machine Learning-Based Overall Survival Status Classification and
Cox PH Model Analysis of Selected Unresectable Cancers”, by examining genomic features
such as iAMP21, TCF-HLF, ETV6-RUNX1, MLL Rearranged molecular subtypes, gene
expression type, fraction of genome altered and clinical features such as age at diagnosis, cell of
tumor origin (T-cell & B-cell), we build an ensemble-based predictive model to classify overall
survival status of unresectable cancers namely acute lymphoid leukemia, colorectal
adenocarcinoma, glioblastoma, and pediatric neuroblastoma. Also, we used the same features for
the Cox PH survival analysis model.
Chapter 5 includes a manuscript currently under preparation for submission to a peer-reviewed
journal. We built a machine learning model to reclassify variants of unknown significance (VUS)
based on established clinical values. The manuscript is titled, “Machine Learning
Reclassification of Variants of Uncertain Significance”.
Chapter 6 includes the general conclusions of this dissertation and the contribution of this study
to cancer therapy research
7
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Machine Learning Classification and Structure-Functional Analysis of Cancer
Mutations Reveal Unique Dynamic and Network Signatures of Driver Sites in
Oncogenes and Tumor Suppressor Genes

Steve Agajanian, Yemi Odeyemi, Nathaniel Bischoff, Simrath Ratra and Gennady Verkhivker
Author’s Contribution
YO contributed to the design of the study and interpretation of the results. YO wrote part of
codes for the data preprocessing and data analysis. All the authors read and approved the final
manuscript.
2.1

Abstract

Background: Cancer arises from the accumulation of somatic mutations and genetic alterations
in cell division checkpoints and apoptosis, this often leads to abnormal tumor proliferation.
Proper classification of cancer-linked driver mutations will considerably help our understanding
of the molecular dynamics of cancer.
Methods: In this study, we compared two cancer-specific predictive models- logistic regression
and random forest for prediction of driver mutations in cancer-linked genes that were validated
on canonical data sets of functionally validated mutations and applied to a raw cancer genomics
data.
Results: By analyzing pathogenicity prediction and conservation scores, we have shown that
evolutionary conservation scores play a pivotal role in the classification of cancer drivers and
were the most informative features in the driver mutation classification. Through extensive
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comparative analysis with structure-functional experiments and multicenter mutational calling
data from Pan-Cancer Atlas studies, we have demonstrated the robustness of our models and
addressed the validity of computational predictions. We evaluated the performance of our
models using the standard diagnostic metrics such as sensitivity, specificity, area under the curve
and F-measure. To address the interpretability of cancer-specific classification models and obtain
novel insights about molecular signatures of driver mutations, we have complemented machine
learning predictions with structure-functional analysis of cancer driver mutations in several key
tumor suppressor genes and oncogenes.
Conclusion: Through the experiments carried out in this study, we found that evolutionary-based
features have the strongest signal in the machine learning classification of driver mutations and
provide orthogonal information to the ensembled-based scores that are prominent in the ranking
of feature importance.
2.2

Introduction
Cancer arises from a gradual buildup of somatic mutations and genetic alterations that

undermine cell division checkpoints and apoptosis, this often leads to abnormal tumor
proliferation (Iranzo et al.,2018; Reddy et al., 2017; Li and Thirumala, 2016). The primary
objective of cancer research is the discovery and characterization of functional effects of variants
that contribute to tumor development. Several DNA sequencing programs have prompted interest
in cancer studies, consequently yielding vital information needed for understanding genomic
basis for tumor development. Somatic variations have been extensively characterized through
deep-sequencing analyses of genome-wide association studies (GWAS) and the coding exomes
of various cancer types, showing that there are ~140 genes whose intragenic mutations contribute
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to cancer, with a relatively small fraction of recurrent somatic variants providing a proliferative
edge to cancer cells and often being detected based on mutational frequency in omics studies.
A large percentage of the somatic mutations are passengers that occur randomly as a result of
mutagenesis, without a known functional impact and biological effect. By analyzing the
variations driving cancer development in more than 7000 tumors, molecular evolution-informed
studies have shown that an insignificant fraction of mutated genes is required to transform a
single normal cell into a cancer cell across diverse cancer types. Novel methods have also
focused on the discovery of presumed drivers in the genome’s non-coding regions. Albeit major
driver mutations can substantially promote tumor proliferation, some passengers can be
singularly weak and yet concertedly lethal, indicating that disease progression is often difficult to
justify based on a classical binary passenger-driver model. Cancer-linked variations that are
inconsequential to tumor proliferation and are present at low frequency in cancer cohorts can
form a set of “mini-drivers”, showing that mutational motifs in cancer genomes are highly
heterogeneous and can span a continuum of phenotypic impacts. Recent NGS breakthroughs
have led to the inauguration of interdisciplinary cancer genomic projects and key data portals,
such as The Catalogue of Somatic Mutations in Cancer (COSMIC) database, The Cancer
Genome Atlas (TCGA) (Weinstein et al., 2013) and the International Cancer Genome
Consortium (ICGC) cancer genome projects(Hudson et al., 2010; Zhang et al., 2011). The
COSMIC database includes data from full exome sequencing of 1020 cancer cell lines. TCGA
data include information about 40 cancer projects from >20 000 genes, ~3.1 million mutations
(Jensen et al., 2017) and 33 cancer types. The ICGC data portal includes 86 cancer projects of 22
cancer primary sites with 81 782 588 annotated simple somatic mutations. (Klonowska et al.,
2016; Hinkson et al.,2017). The cBio Cancer Genomics Portal provides access to cancer
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genomics data sets from >5000 tumor samples, 215 cancer studies, and 981 genes (Cerami et al.,
2012; Gao et al., 2013). Oncogenomics advancement has provided large complex data needed for
data-centric analyses of genetic variations in various cancer types (Nakagawa and Fujita 2018).
In recent times, many bioinformatics tools that compute the structural impact of a given
SNV have been developed for predictions of presumed cancer-linked drivers and functional
annotation of somatic mutations (Cheng et al., 2016; Ding et al., 2014; Raphael et al., 2014).
Computational features for analyzing mutations in the protein-coding regions(Sim et al.,2012;
Adzhubei et al., 2010; Chun et al., 2009; Reva et al., 2011; Schwarz et al., 2010; GonzalezPerez and Lopez-Bigas, 2011; Choi et al., 2012; Shihab et al., 2013) and several sequence-based
scores(Davydov et al., 2010; Garber et al., 2009)were efficiently used for prediction of cancer
driver mutations in the noncoding regions. Combined annotation-dependent depletion (CADD)
and genome-wide annotation of variants (GWAVA) (Kircher et al., 2014; Ritchie et al., 2014)
methods were developed for characterization and classification of the noncoding variants by
combining various genomic annotations into integrated score measures with the aid of support
vector machine classifiers. Cancer driver annotation (CanDrA) (Mao et al.,2013) and cancerspecific high-throughput annotation of somatic mutations (CHASM) (Carter et al.,2009) are
cancer-specific ML approaches that utilized evolutionary, functional and genetic features of
somatic mutations computed by various prediction algorithms. Cancer-related analysis of
variants toolkit (CRAVAT), which is a web-based CHASM application, is now often used for
prioritization of genes and variants important for specific cancer tissue types (Douville et al.,
2013).
In the effort to consolidate a comprehensive functional annotation for SNVs discovered in
exome sequencing studies, a database of human nonsynonymous SNVs (dbNSFP) was
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developed as a one-stop resource for analysis of disease-causing mutations (Liu et al., 2011;
2013; 2016). Based on detailed comparisons and machine learning-based integration of 18
scoring methods for prediction of nonsynonymous SNVs, the two ensemble scores RadialSVM
and LR were designed, showing superior performance over their 10 component scores (Dong et
al., 2015). The latest database dbWGFP of functional predictions for SNVs collected
approximately 8.6 billion possible human whole-genome SNVs, with capabilities to impute a
total of 48 functional prediction scores for each SNV, including 32 functional prediction scores
by 13 approaches, 15 conservation features from 4 different tools including ensemble-based
predictors MSRV, RadialSVM, and LR scores(Wu et al., 2016).
ML studies indicated that the incorporation of both sequence and structure-based scores
can provide important information for classification of cancer genes and driver mutations, but the
underlying molecular reasons for a weak consensus between functional features remains poorly
understood and hidden in the feature selection process. Modern deep learning methods can
leverage large data sets for finding hidden patterns and making robust predictions in cancer
genomics, and drug discovery applications (Angermueller et al., 2016; Zhang et al., 2017; Min et
al., 2016; Jing et al., 2018; Zhou and Troyanskava,2015; Yuan et al., 2016). However, it is often
overlooked that the performance and interpretability of machine learning models are equally
important for predictions and understanding of cancer mutation signatures.
In this study, we compared two ML models, logistic regression (logit) and random forest
(RF) classifiers by considering various cancer-specific golden sets of functionally known cancer
mutations(Carter et al., 2009; Martelotto et al., 2014) and using a set of diverse functional
prediction and conservation scores that included computations of 48 functional scores using
dbWGFP server (Wu et al., 2016). By evaluating a diverse spectrum of functional features, we
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show that conservation-derived and ensemble-based scores were the most informative predictors
in the ML classification of cancer-linked driver mutation. We used logit and RF models to
predict and analyze driver mutations in Cbioportal cancer genomics data set (Cerami et al., 2012;
Gao et al., 2013) by considering 145 601 mutations covering various cancer subtypes and over
300 genes.
2.3

Methods

2.3.1 Data Source and Dataset
We primarily sourced our datasets from Cbioportal, TCGA, and CanDra (from the
COSMIC database). We used various well studied benchmarking data sets of functionally
validated and manually curated variations for our training and validation sets. The initial set
included a total of 3591 SNVs from oncogenes such as HRAS, BRAF, KIT, PIK3CA, KRAS,
EGFR, ERRB2, DICER1, ESR1, IDH1, IDH2, MYOD, SF3B1, and tumor suppressor genes
such as RUNX1, BRCA1, BRCA2 and TP53 (Martelotto et al., 2014). Due to our goal of
classifying mutation as either driver or passenger, we classified neutral and uncertain SNVs as
passenger whereas the driver mutations were left intact. The ML model was trained and
validated only on missense mutations. The first benchmarking had 3706 mutations, with only
3591 SNVs that included 140 neutral, 849 non-neutral, and 2602 of uncertain function which
was assigned as passengers. The second employed data set was taken from the original CanDrA
study (Mao et al.,2013) with 1550 SNVs. The CanDrA data set was initially derived by
combining ovarian carcinoma (OVC) and glioblastoma multiforme (GBM) mutational data
extracted from TCGA (Weinstein et al., 2013) and COSMIC databases (Forbes et al.,2015). In
the GBM sets, 134 SNVs were drivers and 585 SNVs were passenger mutations, while in the
OVC datasets, 122 SNVs were driver mutations and 709 were passengers (Figure 2-2). The
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CanDra data set (Mao et al., 2013) was integrated with the benchmarking data set (Martelotto et
al., 2014) to generate one master training set used to build the ML models. The tree-based
random forest and logistic regression classification models were used to predict cancer-linked
driver variants from the cBioPortal cancer genomics data set (Cerami et al., 2012; Gao et al.,
2013) by considering data from over 200 cancer studies covering 20 primary cancer sites (ovary,
thyroid, CNS/brain, prostate, kidney, bowel, lymphoid, stomach, bladder, head/neck, breast,
myeloid, uterus, lung, PNS, skin, liver, pancreas, soft tissue, cervix).

Figure 2-1 Bar plot showing the distribution of cancer-linked driver mutation in glioblastoma
multiforme and ovarian carcinoma

Figure 2-2. Bar plot showing the distribution of studied cancer genes and mutations from
Cbioportal database
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Table 2-1 Some of the studied genes from Cbioportal database categorized by cancer subtypes

Protein function

Genes

Cell death regulation
signaling

NFKB1, NFKB2, CHUK, DIRAS3, FAS, HLA-G, BAD, BCL2,
BCL2L1, APAF1, CASP9, CASP8, CASP10, CASP3, CASP7,
CASP6, GSK3B, ARL11, WWOX

Telomere Maintenance

TERC, TERT

RTK

EGFR, ERBB2, ERBB3, ERBB4, PDGFA, PDGFRB, KIT, FGF1,
IGF1, IGF1R, VEGFA, VEGFB, KDR

Signaling
P13K-AKT-mTOR
signaling

PIK3CA, PIK3R1, PIK3R2, PTEN, PDPK1, AKT1, AKT2,
FOXO1, FOXO3, MTOR, RICTOR, TSC1, TSC2, RHEB,
AKT1s1, RPTOR

Ras-Raf-MEK-Erk/JNK
signaling

KRAS, HRAS, BRAF, RA1, MAP3K1, MAP3K2, MAP3K3,
MAP3K4, MAP3K5, MAP2K1, MAP2K2, MAP2K3, MAP2K4,
MAPK1, MAPK3, DAB2, RAB25

Regulation of ribosomal
protein synthesis

RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, EIF5A2, EIF4E,
EIF4EBP1, RPS6, HIFIA

Angiogenesis

VEGFA, VEGFB, KDR, CXCL8, CXCR1, CXCR2

Folate transport

SLC19A1, FOLR1, FOLR2, FOLR3, IZUMO1R

Invasion and metastasis
genes

MMP1, MMP2, MMP3, MMP7, MMP9, MMP10, MMP11,
MMP12, MMP13, MMP14, MMP15, MMP16, MMP19, MMP28,
ITGB3, ITGB3, PTK2, CDH1, SPARC, WFDC2
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A total of 80,081 unique missense mutations from 378 cancer genes was considered (after
excluding 65 520 duplicate mutations in patients with multiple samples from a total of 145 601
mutations Figure 2-2). glioblastoma/TP53 pathway genes; glioblastoma/RTK/Ras/PI3K/AKT
signaling genes; glioblastoma/RB pathway genes; Genes implicated in multiple cancer types and
associated with the following major functions: cell cycle control genes; DNA damage response
genes; growth/proliferation signaling genes; RTK signaling genes; p53 signaling genes; notch
signaling genes survival/cell death regulation signaling genes; telomere maintenance genes; RasRaf-MEK-Erk/JNK signaling genes; PI3K-AKT-mTOR signaling genes; regulation of ribosomal
protein synthesis and cell growth genes; angiogenesis genes; folate transport genes; invasion and
metastasis genes. A total of 56,634 unique missense mutations were finally analyzed and
classified by our RF and logit models (Table 2-1).
2.3.2 Machine Learning: Random Forest and Logistic Regression Classifiers
Several factors were considered in the choice of our classifiers for our models such as
easy interpretation, speed (run time) and statistical importance. Afterward, we used and
compared the performance of logistic regression (logit) and random forest (RF). Logistic
regression (logit) is an ML classifier that is used to predict the probability of a categorical binary
outcome. In logit, the dependent variable is a dichotomous(binary) in nature that contains data
coded as 0 or 1. It answer questions such as how does the probability of obesity (yes/ no) change
for every additional can of soda drank per day? Logit models the log odds of an event. Logistic
regression models are based on specific statistical assumptions such as the target variable takes
the form of a binomial distribution, the absence of outliers in the data and no multicollinearity
among the predictors.
Mathematically, the logit classifier predicts P(Y=1) as a function of X.
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𝑌

𝑌
) = 𝑏ₒ + 𝑏₁𝑋₁ + 𝑏₂𝑋₂ + ⋯ + 𝑏ₙ𝑋ₙ
𝐿𝑜𝑔 (
1−𝑌

(2.1)

Where (1−𝑌) is the log likelihood of the target variable, 𝑏ₒ is the y-intercept, 𝑏ₙ𝑋ₙ are the slope
coefficient and the predictors.

RF is a tree-based ensemble classifier where each tree is exposed to a random subset of
features and a random subset of samples drawn with replacement. In this model, the number of
trees, the number of features seen by each tree, and the maximum depth of each tree can be tuned
to fit the data. A data point to be classified is passed to every tree in the forest, and the predicted
class is the winner of a collective vote by all trees. Because of the bootstrapped nature of all the
trees in the forest, random forest classifiers are typically robust to noise and can accurately fit
nonlinear relationships present in data. In the framework of this approach, we used Bayesian
optimization to optimize the hyper-parameters of the model with 100 iterations in our
optimization run. By changing values for the hyper-parameters, we monitored how this affects
the F-score which is the harmonic mean of the precision and recall, to obtain the final set of
hyper-parameters. We provided accuracy to the optimizer as the average of 10-fold crossvalidation run across three different random seeds. The final set of hyper-parameters chosen by
Bayesian optimization were maximum depth = 200, maximum features = 32, number of
estimators = 70. The number of estimators determines the number of trees in the forest,
maximum depth determines the maximum depth that each tree can grow to, and maximum
features determine the number of features randomly selected at each node when choosing the
best tree split. The depth of the random forest model and measurements of information Gini
impurity implemented in scikit-learn (Pedregosa et al., 2011) were employed and refined to
achieve the best results and avoid overfitting problem (Biau, 2012)
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𝑐

𝐺𝑖𝑛𝑖 𝑖𝑚𝑝𝑢𝑟𝑖𝑡𝑦 = ∑
𝑖=1

𝑓𝑖 (1 − 𝑓𝑖 )

(2.2)

Where 𝑓𝑖 is the frequency label of i at a node and c is the number of unique labels. The model

training and tuning was done using scikit-learn free software machine learning library for the

Python programming language (pedregosa et al., 2011). In addition, we also explored logistic
regression classification model that allows for fast training and prediction phases of the model
without tuning requirement and need for feature rescaling (Palazon-Bru et al., 2017).
For the model diagnostic, accuracy, recall, precision, and F1 metrics were used to evaluate the
performance of each classifier. These parameters are defined as follows:
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =
𝑅𝑒𝑐𝑎𝑙𝑙 =

𝑇𝑃
𝑇𝑃 + 𝑇𝑁
; 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 =
𝑇𝑃 + 𝐹𝑃
𝑎𝑙𝑙

𝑇𝑃
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 × 𝑅𝑒𝑐𝑎𝑙𝑙
; 𝐹1 = 2
𝑇𝑃 + 𝐹𝑁
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 + 𝑅𝑒𝑐𝑎𝑙𝑙

(2.3)
(2.4)

The true positive (TP) and true negative (TN) are defined as the number of mutations that are
classified correctly as driver and passenger mutations, respectively. Likewise, false positive (FP)
and false negative (FN) are defined as the number of mutations that are misclassified into the
other mutational classes. An F score is a measure of precision and recall and is often used in
binary classification problems. Precision is defined as the number of positive samples the model
predicts correctly (true positives) divided by the true positives plus the false positives. Recall is
defined as true positives divided by true positives plus false negatives. The positive predictive
value (PPV) and negative predictive value (NPV) were assessed for various components of the
model. PPV is defined as the proportion of mutations predicted to be driver mutations that were
experimentally validated as drivers:
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𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑣𝑒 𝑉𝑎𝑙𝑢𝑒 (𝑃𝑃𝑉) =

𝑇𝑃
𝑇𝑃 + 𝐹𝑃

(2.5)

NPV is the proportion of mutations predicted to be passengers that were experimentally
validated as neutral:
𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑣𝑒 𝑣𝑎𝑙𝑢𝑒 =

𝑇𝑁
𝑇𝑁 + 𝐹𝑁

(2.6)

The model performance was evaluated using receiver operating characteristic area under
the curve. The receiver operating curve (ROC) is a graph where sensitivity is plotted as a
function of 1 – specificity. The sensitivity or true positive rate (TPR) is defined as the percentage
of non-neutral mutations that are correctly identified as driver mutations:
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦(𝑇𝑃𝑅) =

𝑇𝑃
𝑇𝑃 + 𝐹𝑁

(2.7)

The specificity or true negative rate (TNR) is defined as the percentage of mutations that are
correctly identified as passengers:
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦(𝑇𝑁𝑅) =

𝑇𝑁
𝑇𝑁 + 𝐹𝑃

(2.8)

The area under the ROC is denoted AUC. A reliable and valid AUC estimate can be interpreted
as the probability that the classifier will assign a higher score to a randomly chosen positive
example than to a randomly chosen negative example. The AUC effectively measures
discrimination of true positive rate versus false positive rate, providing means to evaluate the
ability of the model to correctly classify drivers and passenger mutations.
2.3.3 Mutational Predictor Scores: Feature Selection and Feature Importance Analysis
The first set of selected features were acquired from dbWGFP web server of functional
predictions for human whole-genome single nucleotide variants that provided 32 functional
prediction scores and 15 evolutionary features (Wu et al., 2016).
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Function prediction scores are scores that predict the probability of a SNV to cause a damaging
change in protein function whereas evolutionary scores are scores providing different
conservation metrics of a given nucleotide site across multiple species. Some of the score
features such as RadialSVM, SIFT, PolyPhen, LRT, MSRV, Mutation Assessor ,
MutationTaster, FATHMM, LR ( Dong et al., 2015 ; Sim et al., 2012 ; Adzhubei et al., 2010 ;
Chun and Fay, 2009 ;Wu et al., 2016 ; Reva et al., 2011 ; Schwarz et al., 2010 ; Shihab et al.,
2013) can be applied only to SNVs in the protein coding regions, whereas other scores such as
Gerp++, SiPhy, PhyloP, Grantham, CADD and GWAVA (Davydov et al., 2010 ; Garber et al.,
2009 ; Grantham, 1974 ; Kircher et al., 2014 ; Ritchie et al. , 2014) can evaluate SNVs spreading
over the whole genome. The ensemble-based scores RadialSVM and LR are integrated features
that used support vector machine (SVM) and LR machine learning approaches to combine
information from 10 individual component scores (SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR,
Gerp++, MutationTaster, Mutation Assessor, FATHMM, LRT, SiPhy, PhyloP), as well as the
maximum frequency observed in the 1000 genomes populations (Dong et al., 2015).
In the final dataset, we imputed 48 feature scores for each SNV (Wu et al., 2016) and the
resulting data set was divided into training and test sets: 80-20% ratio respectively. Our resulting
dataset was preprocessed to handle missing values, skewness, distribution disparity etc.
The training data was subjected to stepAIC feature selection, where features are dropped in a
step by step manner based on each feature statistical significance hierarchy, and the model
trained on the resulting features. After the feature selection resulting in a final data set of 32
features.
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2.4

Results and Discussion

2.4.1 ML Classification of Cancer Driver Mutations on Canonical Data Sets: EnsembleBased and Conservation Features Consistently Outperform Structural Scores

Logit and RF models were trained by examining a combination of two canonical cancerspecific sets of functionally validated mutations (Carter et al., 2009; Martelotto et al., 2014) and
using a group of various predictors that included functional scores obtained from dbWGFP
server (Table 2-2). In this analysis, we compared the performance of both classifiers and focused
on identifying statistical significant predictors that drive cancer predictions in both models
(Figure 2-3). In accordance with prior studies, the ensemble-based scores LR and RadialSVM
dominated the feature importance distribution in both models, significantly outweighing the
importance of other predictors (Figure 2-3A, B). In the RF model, the LR and RadialSVM scores
were the top ranked predictors with the information value scores of 0.27 and 0.23 respectively,
followed by a group of sequence-based evolutionary conservation predictors (Mutation Assessor,
Gerp++, GerpRS, SiPhy, and PhyloP) that also showed significant feature importance (Figure 23A)
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Figure 2-3. Feature importance analysis of the RF and logit machine learning models on the
canonical cancer-specific data set of functionally validated mutations. Feature importance of a
final data set of 32 features in machine learning predictions using RF model (A, B) and logit
model (C,D). Feature importance is measured using the information value and weight of
evidence criteria. (A) Feature importance analysis of the RF model including all 32 features. (B)
Feature importance analysis of the RF model after excluding two top ensemble-based features
LR and RadialSVM. The feature importance values are shown in blue filled bars and annotated.
(C) Feature importance analysis of the LR model including all 32 features. (D) Feature
importance analysis of the LR model after excluding two top ensemble-based features LR and
RadialSVM. The feature importance values are shown in red filled bars and annotated. The
information value (IV) metric typically indicates that attributes with less than 0.02 score have no
predictive power, while those that fall between 0.02 and 0.1 are considered to have weak
predictive power, the features with importance values in the range 0.1–0.2 indicate medium
predictive power, and the features with importance exceeding 0.2 often indicate strong predictive
power.
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Interestingly, the ensemble features RadialSVM and LR integrate information from
components that individually also indicate a substantial information value (GERP++,
MutationTaster, Mutation Assessor, FATHMM, LRT, SiPhy, and PhyloP). LR and RadialSVM
features were initially developed to differentiate non-pathogenic polymorphisms from
pathogenic (mutant) missense variants (Dong et al., 2015). The major rationale behind
consideration of ensemble-based scores alongside with individual components they include was
therefore to evaluate transferability and performance of various predictors for passenger/driver
classification. In this analysis, we compared the two ensemble-based scores, both with each other
and with all other features. The variable importance analysis confirmed that the ensemble based
LR and RadialSVM dwarfs’ other features in both models. Despite these scores reversed rank in
the logit model, they remained the top two features with the information scores of 0.332 and
0.441 for LR and RadialSVM scores respectively (Figure 2-3B). Another significant observation
of feature importance analysis was that the ensemble predictors not only eclipse their own
component scores but also demonstrated greater importance than all the other predictors.
To evaluate the models ability to recap the predictions in the absence of two ensemblebased metrics, we repeated our experiments by excluding the ensemble-based metrics and
ranked the importance of the remaining mutational scores based on their statistical significance
(Figure 2-3,C,D). The top ranked features were commensurable to functional scores based on
evolutionary conservation patterns, such as Mutation Assessor, which was derived to evaluate
sequence homology of protein families and subfamilies within and between species using
combinatorial entropy formalism (Reva et al., 2011). Other highly ranked individual features
included GerpN neutral evolution score and Gerp element scores (Davydov et al., 2010) that
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estimate amino acid substitution deficits to identify constrained elements in multiple alignments.
Also, a similar feature importance ranking was observed in the RF-based application of a
different ensemble learner REVEL (rare exome variant ensemble learner) developed for
predicting pathogenicity of missense variants, (Ioannidis et al., 2016) where the ensemblederived predictors along with Gerp++ and Mutation Assessor individual scores also showed the
highest feature importance. Another significant observation of our analysis was that a group of
evolutionary-based features (GerpRS, GerpN, Gerp++, Mutation Assessor) can be adequately
potent not only for prediction of pathogenic missense SNVs but also in cancer-specific
passenger/driver classification of somatic mutations.
In the logit model, MSRV, SinBAD_HVAR, and SinBAD_HGMD scores were the topranking scores. MSRV, an integrated feature obtained from a set of 24 physicochemical
properties and several conservation scores to compute disease-causing nonsynonymous SNV
mutations (Jiang et al., 2007). SinBaD scores is also an integrated feature that were initially
developed by a logistic regression model with ninety binary features derived from multiple
sequence alignment designed for evaluation of mutational effects in protein coding and promoter
regions (Lehmann and Chen et al., 2013). Another highly ranked feature was likelihood ratio test
(LRT) score that adopted the log-likelihood ratio of the conserved relative to the neutral model to
predict functional significance of mutations (Chun and Fay 2009). Noteworthily, some of the
top- ranking features such as SiPhy, PhyloP, and Grantham were initially developed to provide
prediction scores for variants spreading over the whole genome. Concurrently, functional scores
that estimate the impact of mutational variants on the protein coding regions (MutationTaster,
LRT, SIFT, PolyPhen2_HVAR) contributed less significantly to the feature performance
(Figure2-3 C,D). Some of the population-based scores that differentiates pathogenic missense
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mutants from the typical polymorphisms (SIFT, PolyPhen2) were not as important in our
classification models than cancer-specific features, such as FATHMM designed to distinguish
somatic drivers (Figure 2-3 C, D).
Conversely, we assessed for multicollinearity among each feature of the integrated scores
so as to identify dominant individual components and leverage the complementary of different
prediction algorithms for model performance augmentation. The importance measure for an
individual feature can reflect correlations with other features as well as its intrinsic predictive
ability because importance may be shared among correlated features. Collinearity indicates a
linear relationship in a model. When features are highly correlated, they cannot independently
predict the value of the response variable. In statistical terms, they reduce the significance of the
features. To assess for possible redundancies in our model, we computed and analyzed
Spearman’s rank pairwise correlations between different prediction scores (Figure 2-4). From
our analysis, RadialSVM and LR are highly correlated with one of its original component scores,
Mutation Assessor, and moderately correlated with other top performing sequence-based features
(PhyloP, PhCons, GerpN, GerpRS, and GerpS). These independent features recorded high
correlation with cancer pathogenicity and can provide classification of cancer driver variations.
In our logit model, we observed a significant correlation between RadialSVM and other
ensemble-based SinBAD_HVAR,SinBAD_HGMD and MSRV scores (Figure 2-4 B).
Synchronously, the ensemble scores were only moderately correlated with other top performing
sequence-based features - LRT, PhyloP, PhCons, SiPhy, PhyloP, GerpN, GerpRS, and GerpS.
Furthermore, we observed that GerpRS, GerpN, Mutation Assessor and LRT were weakly
correlated with each other and have a fairly low correlation with other scores in the RF model
Figure 2-4 A). Hence, no pairwise high collinearity was observed in the RF model. Our results
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are consistent with the evaluation of functional and conservation scores in prediction of diseasecausing SNVs and application of radial SVM machine learning models to predict patterns of
cancer driver mutations (Dong et al., 2016)

Figure 2-4. Pairwise Spearman’s rank correlation coefficients between different prediction
scores. The heat map of pairwise Spearman’s rank correlation coefficients is shown for top
ranking features in the RF model (A) and logit model respectively (B). The high-ranking features
include ensemble based LR and RadialSVM scores.

Hence, these evolutionary-based features may provide orthogonal information to the ensemble
scores, leading to the superior feature importance of LR and RadialSVM features.
2.4.2 Model Evaluation: Random Forest (RF) and Logistic Regression (Logit)
For the model diagnostics, we compared the predictive performance of logit and RF models as
well the contribution of individual features using area under the curve (AUC) from the receiver
operating characteristic (ROC) plots, in which true positive rate TPR (sensitivity) is plotted as a
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function of 1 – true negative rate TNR (specificity) (Figure 2-5). The plots showed the improved
performance of the RF model after the feature selection process was complete (AUC = 0.97) as
compared to the original AUC = 0.85 for the initial set of features (Figure 2-5A). By analyzing
the contribution of each features to the performance of RF model, we observed that GerpRS
achieved as high performance in the testing data set (AUC = 0.91) as the ensemble-based LR
score (AUC = 0.88) and RadialSVM score (AUC = 0.87) (Figure 2-5 B). These observations
further supported our conclusions that evolutionary conservation scores can often outperform
other features, including ensemble based LR and RadialSVM scores. A comparative AUC
analysis in the presence and absence of top ensemble scores showed only an insignificant effect
on performance of both models (Figure 2-5 C).Interestingly, we observed strong and similar
performance in logit and RF models (AUC > 0.9) on the testing set when the top two ensemble
features were excluded. These findings showed that ensemble-based scores and functional
features based on evolutionary conservation metrics and statistical descriptors of substitution
patterns can dominate feature importance ranking. Despite differences in the prediction scores,
the obtained highly important features reflected a common fundamental signature, namely that
mutations of evolutionarily conserved residues in functional regions are likely to be harmful and
can often signify the emergence of cancer driver mutations. In simpler terms, the probabilistic
evaluation of deleterious mutations that underlies most of the dominant features appeared to be
also sufficient for robust classification of driver mutations in the canonical cancer data.
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Figure 2-5. ROC plots of sensitivity (TPR) as a function of 1 – specificity, where specificity is
TNR. (A) ROC curves for overall performance of the RF model before and after feature
selection. (B) ROC curves for top 5 prediction scores in the RF model. The ensemble-based LR
(AUC = 0.88) and RadialSVM scores (AUC = 0.85) are top performing features in the RF
model. A higher AUC score indicates better performance. (C) Comparison of ROC curves for
RF and LR models with all selected features and without the top two ensemble scores LR and
RadialSVM. These plots illustrated a comparative performance of machine learning models for
top prediction scores.

These findings indicated that ensemble-based scores and functional features based on
evolutionary conservation measures and statistical descriptors of substitution patterns can
dominate feature importance ranking. Despite differences in the prediction scores, the obtained
highly important features reflected a common fundamental signature, namely that mutations of
evolutionarily conserved residues in functional regions are likely to be deleterious and can often
32

signify the emergence of cancer driver mutations. In other words, the probabilistic evaluation of
deleterious mutations that underlies most of the dominant features appeared to be also sufficient
for robust classification of driver mutations in the canonical cancer data sets.
2.5
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3.1

Abstract

Introduction: Incorporation of machine learning with genome-wide association studies in the
prediction of the structural and clinical significance of cancer driver variants are at the forefront
of our understanding of the molecular dynamics of cancer.
Methods: In this study, we integrated two ensemble tree-based classifiers (random forest and
gradient boosting machines) with deep convolutional neural networks (CNN) for prediction of
cancer driver mutations in the genomic datasets. The feasibility of CNN in using raw nucleotide
sequences for classification of cancer driver mutations was initially explored by employing label
encoding, one-hot encoding, and embedding to preprocess the DNA information. These
classifiers were benchmarked against their tree-based alternatives to evaluate the performance on
a relative scale. We then integrated DNA-based scores generated by CNN with various
categories of conservational, evolutionary and functional features into a generalized random
forest classifier.
Results: The results of this study have demonstrated that CNN can learn high-level features from
genomic information that are complementary to the ensemble-based predictors often employed
for the classification of cancer mutations.
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Conclusion: By combining deep learning-generated score with only two main ensemble-based
functional features, we can achieve a superior performance of various machine learning
classifiers.
3.2

Introduction
Recent advances in next-generation sequencing (NGS) platforms have yielded a large

amount of cancer genomic data which can be leveraged for classifying driver genes. With the
increasing number of validated driver mutations, researchers began utilizing machine learning
models to predict new cancer-linked drivers. The explosion of data generated in genome-wide
association study (GWAS) and next-generation sequencing (NGS) has been the motivation for
the development of large bioinformatics data resources such as The Cancer Gene Census of the
Catalog of Somatic Mutations in Cancer (COSMIC) database (http://cancer.sanger.ac.uk),
Cancer Genome Atlas (TCGA), Genomics Data Commons Portal
(https://portal.gdc.cancer.gov/), the International Cancer Genome Consortium (ICGC) and
formation of international cancer genomic projects. (Forbes et al., 2015; Weinstein et al.,
2013; Jensen et al., 2017; Hudson et al., 2010; Zhang et al., 2011; Klonowska et al.,
2016; Hinkson et al., 2017 ). COSMIC has evolved from ~290 well-characterized cancer genes
(Futreal et al., 2004) to more than 500 entries (Forbes et al., 2015) where some cancer genes can
be commonly mutated across cancer types, while other genes are mostly cancer-specific. The
Cancer Genomics Portal (cBioPortal) (https://www.cbioportal.org/) is an open-access resource
for big data cancer genomics analyses (Cerami et al., 2012; Gao et al., 2013). These datasets
have allowed for robust genome-wide analyses of genetic variation in various cancer types
(Poulos and Wong, 2018). A comparatively small percentage of somatic variants known as
driver mutations have substantial biological effects and can be amassed over a period of time as a
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result of a range of mutational processes, rather than inherited (Haber and Settleman,
2007; Lawrence et al., 2013; Vogelstein et al., 2013). A robust analysis of cancer-linked driver
genes and mutations has provided a classification of 751,876 distinct missense mutations,
yielding a dataset of 3,442 functionally validated driver variations (Bailey et al., 2018). Another
substantial dataset of ~1,050 experimentally tested and functionally validated drivers (Ng et al.,
2018) has expanded our knowledge of cancer-linked variants in oncogenes and tumor suppressor
genes. TCGA organized the Multi-Center Mutation Calling in Multiple Cancers (MC3) network
project which produced a complete and consistent collection of somatic mutation calls for the
~10,400 tumor samples data (Ellrott et al., 2018). Computational strategies that evaluate the
impact of somatic mutations are often identified by types of input features, models, prediction
targets such as driver gene, statistical and computational assumptions (Gonzalez-Perez et al.,
2013; Cheng et al., 2016).
Several statistical and ML-based somatic variant callers are now available for somatic
mutation identification and detection, such as VarScan2 (Koboldt et al., 2012), Strelka2 (Kim et
al., 2018), and SomaticSniper (Larson et al., 2012). DeepVariant (deep CNN strategy) can
characterize variants in NGS data by identifying statistical relationships around presumptive
variant sites (Poplin et al., 2018). To enable standardized somatic variant processing from cancer
sequencing data, deep learning (DL) approach and tree-based random forest (RF)were utilized,
showing that these ML methodologies could achieve high and similar classification performance
across all processed variant classes (Ainscough et al., 2018)
Several computational techniques have been proposed for cancer driver genes prediction.
Some of these methods use cohort-based analysis to identify driver genes such as MuSiC (Dees
et al., 2012), OncodriveFM (Gonzalez-Perez and Lopez-Bigas, 2012), OncodriveFML (Mularoni
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et al., 2016) and OncodriveCLUST (Tamborero et al., 2013). The success of hybrid methods for
scoring coding variants has indicated that the integration of different tools may enhance
predictive accuracy for both coding and non-coding variants (Li et al., 2015). DeepDriver- A
deep learning-based method predicts driver mutations by CNN trained with a mutation-based
feature matrix constructed using similarity metrics (Luo et al., 2019). Since various approaches
are often found to predict unique or partially overlapping subsets of cancer driver mutations, a
consensus-based strategy was recently proposed, showing considerable promise and
outperforming the individual approaches (Bertrand et al., 2018). An integrated ML-based
evaluation framework for the analysis of driver gene predictions compared to the performance of
these approaches, indicating that the driver mutations predicted by each tool can differ
significantly(Tokheim C. et al., 2016; Tokheim C. J. et al., 2016).
Computational strategies formulated to characterize driver genes have become
increasingly crucial to facilitate an automated evaluation of biological and clinical effects
(Raphael et al., 2014; Gnad et al., 2013; Martelotto et al., 2014; Cheng et al., 2016; Ding et al.,
2014). Functional computational prediction methods include Functional Analysis Through
Hidden Markov Models (FATHMM) (Shihab et al., 2013), Sorted Intolerant From Tolerant
(SIFT) (Sim et al., 2012), PolyPhen-2 (Adzhubei et al., 2010), Mutation Assessor (Reva et al.,
2011), MutationTaster (Schwarz et al., 2010) and Protein Variation Effect Analyzer
(PROVEAN) (Choi et al., 2012). Cancer-specific High-throughput Annotation of Somatic
Mutations (CHASM) (Carter et al., 2009; Douville et al., 2013; Masica et al., 2017), Cancer
Driver Annotation (CanDrA) (Mao et al., 2013), and FATHMM (Shihab et al., 2013). Many new
approaches have recently addressed a problem of locating driver mutations within the noncoding genome regions (Piraino and Furney, 2016).To consolidate functional annotation for
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SNVs discovered in exome sequencing studies, a database of human non-synonymous SNVs
(dbNSFP) was developed (Liu et al., 2011, 2013, 2016; Dong et al., 2015; Wu et al., 2016). This
resource allows for the computation of a total of 48 functional prediction scores for each SNV,
including 32 functional prediction scores by 13 approaches and 15 conservation features (Wu et
al., 2016). In our recent investigation, two cancer-specific machine learning classifiers were
proposed that utilized 48 functional scores from the dbWGFP server in the classification of
cancer driver mutations (Agajanian et al., 2018).
In this study, we explore and integrate RF and deep convolutional neural network (DCNN) ML methods for the classification and prediction of cancer driver genes. Initially, we
explore the feasibility of CNN models to classify cancer driver mutations directly from raw
nucleotide sequence information without the predetermined functional scores. The performance
of these classifiers was compared with tree-based classifiers (RF and gradient boosting machines
-GBM) algorithms to provide a comparative evaluation of different classification models. These
raw sequence-derived scores are advantageous because they can be obtained for any mutation
with a known chromosome and position, whereas the functional scoring features can be limited
to subsets of genomic mutations. By designing a practical classification algorithm that could
leverage information from raw DNA nucleotides, classifiable mutations domain can be
immensely broadened resulting in more general and robust ML tools. The results of this study
reveal that CNN models can learn high importance features from genomic information that are
complementary to the ensemble-based predictor scores traditionally used in ML classification of
cancer mutations. We show that integration of the DL-derived predictor score with only several
ensemble-based features can improve performance in capturing driver mutations across a
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spectrum of ML classifiers and recapitulate the results obtained with a large number of
functional features.
3.3

Materials and Methods

3.3.1 Data Source
Our primary data sources are cBioPortal (https://www.cbioportal.org/), University of
California, Santa Cruz (UCSC) Genome Browser (http://genome.ucsc.edu/) and dbWGFP web
server CBioPortal is a publicly curated database hosted by Center for Molecular Oncology at
Memorial Sloan Kettering Cancer Center (MSK) (Cerami et al., 2012 & Gao et al., 2013).
UCSC Genome Browser is an open access repository offering genome sequence data from a
variety of vertebrate and invertebrate species and major model organisms, integrated with a large
collection of aligned annotations. It is hosted by the University of California, Santa Cruz (UCSC)
(Tyner et al., 2017). The dbWGFP is a web server of human whole-genome single nucleotide
variants and their functional predictions (Wu et al., 2016).
3.3.2 Dataset and Feature Selection
In our previous work, (Agajanian et al., 2018) we used RF classifier to predict cancerlinked drivers using two consolidated golden datasets (Mao et al., 2013; Martelotto et al.,
2014). In this study, we expanded this dataset by including the passengers from the missense
mutations analysis and predicted cancer driver mutations in Cbioportal database (Agajanian et
al., 2018). Based on our prior analysis, we generated a dataset consisting of functionally
validated 12,941 passenger mutations and 6,389 cancer driver mutations. The passenger/driver
classifications for 2,570 of these mutations were present in the two previous golden datasets, and
our RF classifier made predictions on the remaining 16,760 missense mutations from the
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Cbioportal database. From the performance of our initial model (Agajanian et al., 2018), we
hypothesize that the incorporation of the missense mutations in the Cbioportal database with the
two golden datasets would produce an informative dataset for this study. The features used for
the initial random forest predictions were retrieved from dbWGFP web server (Wu et al., 2016)
of functional predictions for human whole-genome single nucleotide variants. A total of 32
sequence-based, functional and evolutionary features characterized in our prior study (Agajanian
et al., 2018) were initially used for ML studies with the new dataset of cancer mutations. In
cancer driver mutation predictions, traditional input data comprise of unique features that cannot
be directly used in CNN models due to their lack of spatiality in the data. Using chromosomal
position that corresponded to the mutated nucleotide, we could obtain the surrounding
nucleotides of the mutation of interest to perform classification with only this raw string of
nucleotides. For easier representation of the original nucleotide and its mutated version, we
placed two nucleotide sequences on top of each other, one containing the original nucleotide, and
the other contained the mutated copy. This would only result in a one nucleotide difference
between the two, allowing to effectively utilize CNN’s sliding window mechanism.
The schematic workflow diagram of the CNN approach employed in this study is presented in
Figure 3-1
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Figure 3-1. The schematic workflow diagram of the CNN approach employed in this study. To
determine the optimal architecture, we performed a grid search over a total of 72 different neural
network architectures. These 72 architectures consisted of between 1 and 3 convolutional layers
and 1–3 fully connected layers following. The number of nodes in each of these layers was also
varied between 2 and 256 in powers of 2. The simplest architecture covered in this search
contains 1 convolutional layer with 2 filters feeding into 1 fully connected layer with 2 nodes,
and the most complex would have 3 convolutional layers feeding into 3 fully connected layers,
all containing 256 nodes.

To generate this dataset, we parsed information from University of California, Santa Cruz
(UCSC) Genome Browser (http://genome.ucsc.edu/) (Tyner et al., 2017) which takes a
chromosome (CHR) and a position (POS) on that chromosome as arguments and returns all
nucleotides within the sequence. To generate this dataset, we parsed information from the
University of California, Santa Cruz (UCSC) Genome Browser (http://genome.ucsc.edu/) (Tyner
et al., 2017) which takes a chromosome (CHR) and a position (POS) on that chromosome as
arguments and returns all nucleotides within the sequence. Using the dataset containing 6,389
driver mutations and 12,941 passengers, we were able to obtain five different datasets of various
window sizes around each given CHR/POS pair. The explored window sizes (10, 50, 100, 500,
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and 5,000) produced nucleotide strings of length 21, 101, 201, 1,001, and 10,001, respectively.
To represent the type of mutation (A->C, A->G, etc.) we stacked two of the same nucleotide
sequences on top of each other, having one contains the original nucleotide at the position passed
in initially, and the other containing the mutated version (Figure 2A). This computation yielded a
total input matrix size of (2, 21), (2, 101), (2, 201), (2, 1001), and (2, 10001), respectively. Three
various preprocessing techniques were then applied to the dataset to allow it to be passed into the
CNN model in the numerical form: label encoding (Figure 2B), one-hot encoding (Figure
2C; Goh et al., 2017), and embedding (Figure 2D). Label encoding works by designating each
nucleotide its own unique ID (A = 0, C = 1, G = 2, T = 3) This introduces a ranking system on
the nucleotide sequences that may have implications for the neural network learning (Figure 2B).
This technique was implemented using the Scikit-learn LabelEncoder package for the Python
programming language. We also tried introducing dummy variables (one-hot encoding) to the
dataset by designating each nucleotide its own bit encoded string (A = [0,0,0,0,1], C= [0,0,0,1,0],
G =[0,0,1,0,0], T = [0,1,0,0,0) (Figure 2C). This tends to be a favorable preprocessing function
for weight-based classifiers because no ranking system is imposed on the samples. This approach
tends to be the representation choice for discrete features due to its interpretation by default.
Because each nucleotide gets its own index in a 5-bit string, a 1 in any particular index means
that nucleotide is present in that location. For example, since A = [0,0,0,0,1], this can essentially
be read as “There are 0 ‘n,' 0 ‘g,' 0 ‘t,' 0 ‘c,' and 1 ‘a' nucleotides present at this location.” Since
the one-hot encoding preprocessing technique complicates the string, the resulting
dimensionalities were (2, 105), (2, 505), (2, 1005), (2, 5005), and (2, 50005), respectively.
The final preprocessing method employed for the DNA sequences involved learned embeddings
created with the word2vec algorithm (Mikolov et al., 2013). This approach analyzes the
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sequential context of the nucleotides assigning them a numeric representation in vector space.
Using this representation, the nucleotide segments with similar meaning in the word2vec model
would yield similar vectors in an N-dimensional representation. This technique was implemented
using the Word2Vec model from the genism library for the Python programming language. Since
the vocabulary in this application is fairly small, consisting of only 5-bit components, we chose
to convert the nucleotide to 2-dimensional vectors which are sufficient to effectively encode this
set. This resulted in the input sizes (2, 42), (2, 202), (2, 402), (2, 2002), and (2, 20002),
respectively (Figures 3-1,3-2). The implementation and execution of these three preprocessing
techniques provides adequate and efficient nucleotide representations for the CNN classifier.
3.3.3 Machine Learning Models
We used and compared the performance of CNN models and ensemble(tree-based)
classifiers. For the ensemble methods, we adopted our earlier established protocol for obtaining
hyper-parameters (Agajanian et al., 2018). The model training and tuning were done using the
Sklearn open-source ML library for the Python programming language (Pedregosa et al., 2011;
Biau, 2012). The Keras framework was used for training, validation, and testing of CNN models
(Erickson et al., 2017). The dataset was partitioned into training and test set in a 70%-30% ratio.
Due to the skewness of the label in favor of passenger mutation, oversampling and undersampling techniques were used to address potential bias in the prediction models (Blagus and
Lusa, 2013). To handle for overfitting in our models, we performed five-fold cross-validation,
splitting the training set up into 5 equal-sized subsets. The model trains on four subsets and
predicts the fifth. This is repeated five times so that each of the five subsets has been predicted
on.
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Figure 3-2. Preprocessing of the nucleotide information for CNN machine learning of cancer
driver mutations. Two different preprocessing techniques were then applied to the dataset to
allow it to be passed into the CNN model in the numerical form: label encoding and one-hot
encoding. (A) A schematic diagram of window sliding protocol. To represent the original
nucleotide and its mutated version, two nucleotide sequences are placed on top of each other, one
containing the original string, and the other containing the mutated version. This representation
allows to utilize the sliding window format of the CNN models. (B) A schematic diagram of
label encoding preprocessing protocol. Label encoding assigns each nucleotide its own unique
ID (A->0, C->1 etc.) This imposes an ordering on the nucleotide sequences. (C) A schematic
diagram of one hot encoding preprocessing protocol. One-hot encoding assigns each nucleotide
its own bit encoded string (A -> [0,0,0,0,1], C-> [0,0,0,1,0]). This tends to be a favorable
preprocessing function for weight-based classifiers because no artificial ordering is imposed on
the samples. (D) A schematic diagram of the embedding preprocessing scheme created with the
word2vec algorithm.
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A workflow diagram of the CNN approach (Figure 3-1) was engineered to determine the
optimal architecture. For this, we performed a grid search over a total of 72 different neural
network architectures. These 72 architectures consisted of between 1 and 3 convolutional layers
and 1–3 fully connected layers following. The number of nodes in each of these layers was also
varied between 2 and 256 in powers of 2. The simplest architecture covered in this search
contains 1 convolutional layer with 2 filters feeding into 1 fully connected layer with 2 nodes,
and the most complex would have 3 convolutional layers feeding into 3 fully connected layers,
all containing 256 nodes. The ReLU activation function was used, which returns max (0, X). All
72 different architectures (Table 3-1) were tested using this cross-validation algorithm and the
architecture that had the highest F1 score across all 3-folds was chosen. Our neural networks
were trained for 100 epochs, which means that they will pass through the entire dataset 100 times
to complete their training. In between each epoch, the model recorded its predictions on the
validation fold, and the epoch with the best performance on the validation set was recorded. The
best architecture was used for predictions on the test set. Dropout layers was added in between
layers so that inputs into a layer are randomly set to 0 with a certain probability. This prevents
overfitting in the model, forcing it to learn without random features present.
To evaluate the performance of each model, several metrics such as accuracy, precision, recall
and F1 score were calculated to assess the performance of classification models. These
parameters are defined as follows:
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =

𝑅𝑒𝑐𝑎𝑙𝑙 =

𝑇𝑃
𝑇𝑃 + 𝑇𝑁
; 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 =
𝑇𝑃 + 𝐹𝑃
𝑎𝑙𝑙

𝑇𝑃
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 × 𝑅𝑒𝑐𝑎𝑙𝑙
; 𝐹₁ = 2
𝑇𝑃 + 𝐹𝑁
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 + 𝑅𝑒𝑐𝑎𝑙𝑙
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(3˗1)

( 3˗2)

True Positive (TP) and True Negative (TN) are defined as the number of mutations that are
classified correctly as driver and passenger mutations, respectively. False Positive (FP) and
False Negative (FN) are defined as the number of mutations that are misclassified into the other
mutational classes.
Table 3-1. The parameters of displayed CNN architectures in classification of cancer driver
mutations
Architecture

No of Layers

No of Nodes Per Layer

0

2

32,2

1

3

16,8,2

2

3

16,16,2

3

3

32,16,2

4

3

32,8,2

5

3

64,32,2

6

3

64,16,2

7

4

64,64,16,2

8

4

128,64,16,2

9

4

128,64,32,2

10

5

128,64,32,16,2

Precision is defined as the proportion of positive samples the model predicts correctly (true
positives) divided by the true positives plus the false positives. Recall is defined as true positives
divided by true positives plus false negatives. The model performance was evaluated using
receiver operating characteristic area under the curve. The receiver operating curve (ROC) is a
graph where sensitivity is plotted as a function of 1-specificity.
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The area under the ROC is denoted AUC. The sensitivity or true positive rate (TPR) is defined as
the percentage of non-neutral mutations that are correctly identified as driver mutations:
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦(𝑇𝑃𝑅) =

𝑇𝑃
𝑇𝑃 + 𝐹𝑁

(3˗3)

The specificity or true negative rate (TNR) is defined as the percentage of mutations that are
correctly identified as passengers:
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦(𝑇𝑁𝑅) =

𝑇𝑁
𝑇𝑁 + 𝐹𝑃

(3˗4)

These metrics allow us to differentiate models by providing assessment options to
properly evaluate the performance of a model. F1 score, recall and precision were the primary
discriminatory metrics we used to evaluate classification performance. Under this data
distribution, a model that only predicted passengers would yield an accuracy of 66.95%, but an
F1 score of 0. In the case that two models exhibited the same F1 score, we used the AUC score
as an alternative evaluation measure. The AUC score summarizes the trade-off between the TPR
and FPR for a predictive model using a number of probability thresholds. AUC measures the
entire two-dimensional area underneath the entire ROC curve (think integral calculus) from (0,0)
to (1,1). A powerful classifier learns a likelihood function that consistently maps instances of the
negative class to likelihoods lower than the positive class. A model that is reliable able to do this
would receive an AUC of 1, whereas a model that only predicted the negative class would also
receive an AUC of 0. They are appropriate when the observations are balanced between each
class, whereas precision-recall curves are appropriate for imbalanced datasets.
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3.4

Results

3.4.1 Deep Learning Classification of Cancer Driver Mutations from Nucleotide
Information
We started by trying to recapitulate our predictions by using a number of CNN
architectures informed by raw nucleotide sequence data that assessed the ability to make
predictions based mainly on raw genomic data. The combination of the 3 various preprocessing
methods enabled us to select the most informative representation of the nucleotides. The one-hot
encoded sequences produced the model with the best performance, and for simple representation
we reported only the dimensions and performance of the one-hot encoded model. This
preprocessing model resulted in input matrices of size (2, 105), (2, 505), (2, 1005), (2, 5005), and
(2, 50005) corresponding to the different window sizes (10, 50, 100, 500, 1,000) surrounding the
original nucleotide. Noteworthily, that the word2vec algorithm also learned meaningful
representations of the nucleotides. The missing place indicator, “n,” was predictably separated
from the original nucleotides, which were arranged in 2 neat clusters (Figure 3D). Cluster 1
consisted of the tyrosine (T) and adenine (A) nucleotides, and cluster 2 comprised of cytosine
(C) and guanine(G) nucleotides. These two clusters are easily identified due to the fact that their
constituent components are very close to each other while simultaneously being far away from
the other cluster.
We used the 72 different deep learning architectures (Table 3-1) and the results for the window
size of 10 are presented since they revealed more variance (Figure 3-3). The figures below
display the 10 best performing models out of the 72 models. The training accuracy continued to
increase for the duration of training (Figure 3-3A), while on the validation testing set of cancer
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mutations, the best DL architecture achieved an average validation accuracy of 86.68% with an
F1 score of 0.61 (Figure 3-3B).

Figure 3-3. The average accuracy of CNN models using exclusively nucleotide information.
(A) Average accuracy across all 3-folds on an epoch by epoch basis on the training set with the
sliding window size = 10. (B) Average accuracy across all 3-folds on an epoch by epoch basis on
the validation set with the sliding window size = 10.

Noteworthily, we discovered that the CNN model seemed to learn early on, overfitting
with each successive epoch (Figure 3B). In fact, the model had its highest validation accuracy on
the first epoch, and subsequently declined after. Furthermore, the AUC and F1 scores of the
model plateaued all through the computation process. This is further contextualized by the
ensembled method's performance on the same dataset. The RF classifier exhibited an average
validation accuracy of 69.86% and F1 measure of 0.58, and the GBM classifier recorded an
average validation accuracy of 66.59% and an F1 measure of 0.57. Although we investigated a
number of different architectures using various nucleotide-encoding protocols, a direct bruteforce application of DL/CNN models to predict driver mutations only as a function of
surrounding nucleotides appeared to be challenging. As a result, we employed a number of
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informative features to recapitulate the level of robust performance achieved in our earlier work
with functional features and sequence-based conservation (Agajanian et al., 2018).
Initially, we used the random forest classifier on the cancer mutation dataset with
conservation and functional features retrieved from dbWGFP server and used in our earlier
study (Agajanian et al., 2018). A repository of human non-synonymous SNVs (dbNSFP) was
developed with the goal of providing resources for disease-causing mutations analysis (Liu et al.,
2011, 2013, 2016; Dong et al., 2015; Wu et al., 2016) storing ~8.5 billion possible human wholegenome SNVs, with capabilities to compute a total of 48 functional prediction scores for each
SNV, including 15 conservation features from four various tools including ensemble-based
features MSRV, RadialSVM and LR scores; and 32 functional prediction scores by 13
approaches. Evolutionary scores refer to scores providing different conservation measures of a
given nucleotide site across multiple species. Whereas, functional prediction scores refer to
scores that predict the likelihood of a given SNV to cause a deleterious functional change in the
protein. Some of the features such as GWAVA, Grantham, Gerp++, SiPhy, PhyloP and CADD
can evaluate SNVs spreading over the whole genome. Whereas, other scores such as FATHMM,
SIFT, PolyPhen, SinBaD, LRT, RadialSVM, LR, MSRV, Mutation Assessor and MutationTaster
can be applied only to SNVs in the protein coding regions. The ensemble-based scores LR and
RadialSVM are integrated predictors that used ML methods to combine information from ten
individual component scores (LRT, FATHMM, SiPhy, PhyloP, SIFT, PolyPhen-2 HDIV,
PolyPhen-2 HVAR, Gerp++, MutationTaster, Mutation Assessor) (Agajanian et al., 2018).
In this baseline experiment we analyzed performance of 32 input predictors on the expanded
dataset (Figure 3-4A). Similar to our earlier investigation (Agajanian et al., 2018), we discovered
that the ensemble-based scores RadialSVM and LR considerably overshadowed the contributions
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of other features (Figure 3-4). By incorporating the DL score in the original features set, we
applied the RF model for predicting cancer driver mutations with this expanded set of predictors.
The first question was to evaluate the feature importance of the RF model with the DL score
included and determine whether the nucleotide-based scoring predictors can contribute to the
prediction performance in a significant way (Figure 3-4). In the second step of RF classification
experiments, we added DL score to the original list of 32 features (Figure 3-4B). Interestingly,
the DL score ranked third following the ensemble-based LR and RadialSVM scores (Figure 34B). Moreover, it was evident that these three feature scores completely dominated feature
importance distribution, with the DL score contributing almost as much as the ensemble-based
RadialSVM feature (Figure 3-4B). Quite remarkably, the DL-based score derived by CNN
exclusively from primary nucleotide information can deliver significant information content.

Figure 3-4. (A) Feature importance of 32 functional and sequence conservation features with DL
score feature produced by CNN model excluded. (B) Feature importance of 33 features with the
DL score included in the RF classification. The feature importance values are shown in blue
filled bars and annotated. Feature importance is measured using the information value and
weight of evidence criteria.
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3.4.2 Incorporation of CNN Predictions with Ensemble-Based Predictors in Cancer
Driver Mutations Models
From the preliminary assessment, we analyzed feature selection again with the goal of
recapitulate similar accuracy with only eight predictors: LR, LRT, RadialSVM, DL, GerpRS,
GerpN , verPhyloP, and SiPhy scores (Figure 3-5A). The eight-predictor RF model produced a
similar ranking in which the ensemble-based scores and DL score contributed the most (Figure
3-5A). Evolutionary conservation scores derived from multiple sequence alignments and
reflecting functional specificity, such as SiPhy (Garber et al., 2009) and GerpRS (Davydov et al.,
2010) also showed significant information score values (Figure 3-5A). Subsequently, we tested
the performance of the RF model and feature importance by performing ML of cancer driver
mutations using only top three predictors (Figure 3-5B)

Figure 3-5. (A) Feature importance ranking based on RF classification with only 8 most
informative features. (B) Feature importance ranking based on RF classification with only top
three predictors that included ensemble-based RadialSVM, LR scores, and DL score produced by
CNN model.

61

The predictability of the RF models with various set of predictors was evaluated using area under
the curve (AUC) plots (Figure 3-6).

Figure 3-6. The AUC/ROC plots of sensitivity (TPR) versus specificity (TNR). (A) The ROC
curves for overall performance of the RF model with 32 functional features excluding DL score
(in green) and 33 features that included DL score (in red). (B) The ROC curves for the RF model
with all 33 features (in green) and with the top 3 performing features that included LR score,
Radial_SVM score, and DL score (in red). Higher AUC score indicates better performance.
These plots illustrated a comparative performance of machine learning models for top prediction
scores.
First, we evaluated the difference in the AUC curves for RF-based classification with 32
functional features and with additional DL score (Figure 3-6A). The results showed a very
similar high-level prediction performance with AUC = 0.95–0.96. It is worth noting that due to
high AUC value for RF classification with 32 informative functional features, the addition of DL
could not significantly enhance it. However, we showed that this nucleotide-derived predictor
score provides an additional information content and is complementary to the ensemble-based
RadialSVM score and LR score. In this context, it was instructive to observe that addition of DL
score may marginally improve separation between sensitivity and 1 – specificity (FPR) at higher
values of these parameters (Figure 3-6A).
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Interestingly, RF model that relied on RadialSVM score, LR score, and DL score( top
three predictors) yielded 94% AUC , thereby showing that these predictors may be adequate for
robust classification of cancer driver mutations on a fairly large dataset of somatic mutations
employed in this study. We closely examined the discriminatory ability of the classification
models (Table 3-2).
Table 3-2. Statistics and comparative performance metrics of various ML classification of cancer
driver mutations models for the top eight predictors.
Random forest
Boosted trees
Support vector
machines
False negative rate

0.91

0.91

0.75

True negative rate

0.11

0.12

0.02

False positive rate

0.12

0.11

0.80

True positive rate

0.86

0.85

0.95

Recall

0.90

0.90

0.89

Precision

0.90

0.90

0.89

F1- measure

0.90

0.90

0.89

Accuracy

0.89

0.89

0.89

All algorithms achieved a high classification accuracy of ~90%. The TPR values were higher for
the RF and SVM classifiers, but all algorithms resulted in similar high performance
classification on the dataset with only limited number of major predictors that included DL score
(Table 3-2). Summarily, our findings supported the notion that ML-derived ensemble functional
features may play a cardinal role in classification of driver mutations. The major finding of these
ML experiments was that combination of ensemble-based features and DL score are
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complementary and when combined can yield comparable classification accuracy. The critical
lesson from this analysis is that integrated high-level features obtained by ML strategies from
primary nucleotide and protein sequence information may be adequate for predicting key
functional phenotypes.
3.5
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4.1

Abstract

Background: Acute lymphoblastic leukemia, colorectal adenocarcinoma, glioblastoma, and
neuroblastoma are well studied unresectable cancer types. Ensemble machine learning classifiers
can be used for the analysis of the overall survival status of selected cancer types. The primary
objectives of this study were to build: (1) high accuracy machine learning model to classify
cancer survival status and (2) Cox proportional-hazards survival analysis for pediatric cancers.
Methods: Data for the four selected cancer types were retrieved from the cBioPortal cancer
genome database. The high-performance machine learning approaches, gradient boost machine
(GBM), extreme gradient boosting (XGBoost) and a deep neural network architecture were used
to and trained on the cancer survival datasets. Five survival status models were built for each of
the analyzed cancer types and a fifth one was built for the Memorial Sloan Kettering cancer
center-MSK-IMPACT dataset. Furthermore, Cox proportional- hazards models were
implemented to conduct survival analysis on pediatric acute lymphoblastic leukemia and
pediatric neuroblastoma that allow identification and effect size estimation of the statistically
significant predictors of these cancers.
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Results: The ensemble tree classifiers and the deep neural network model obtained area under
the curves values between 0.75 and 0.95 across all five models. The Cox-proportional- hazards
model showed that age at diagnosis, tumor origin of T-cells( effect size/HR: 0.35) , tumor origin
of B-cells(HR:0.39), congenital abnormality-no(HR: 0.59),congenital abnormality-yes(HR:
8.30), molecular subtype-hyperdiploidy without trisomy of both chromosomes 4 and 10(HR:
0.70) and molecular subtype-iAMP21(HR: 1.67) , TCF3_PBX1_status-negative(HR: 0.76)and
Trisomy 4 and 10 -negative( HR: 1.52) play a significant role in survival rate of pediatric acute
lymphoblastic leukemia. Whereas, in the pediatric neuroblastoma INSS-stages 1(HR: 0.44),
INSS-stage 2a(HR: 0.53),INSS-stage 4(HR: 0.51), INSS stage 4s(HR: 2.69), the number of
complete sets of cellular chromosomes -ploidy_diploid/DI =1 (HR:0.69) and the number of
complete sets of cellular chromosomes-DI>1(HR: 2.39) and gender- male (HR: 0.89) were the
statistically significant features in the Cox PH model.
Conclusion: Machine learning can be used to predict the overall survival status of cancer using
age at diagnosis, mutational profile among other risk factors. Age at diagnosis, cell of tumor
origin, congenital abnormality, molecular subtype, INSS stage, and ploidy make a significant
impact on the survival rate in pediatric cancers.
4.2

Introduction
The burden of cancer in the US is on the rise, there is an incessant need to develop

efficient strategies for prevention and standard care (Allemani et al., 2015; Cavalli & Cavalli,
2013). In 2018, cancer accounted for more than 600,000 deaths in the US (Miller et al.,2018;
NCBI cancer statistics,2018). However, the US has better survival statistics when compared to
most other developed countries (Allemani et al.,2015; Centers for Disease Control and
Prevention, 2019; Gorey, 2009; Coleman et al., 2008). The National Institute of Health (NIH)
74

introduced a couple of programs with a special focus on the early diagnosis as a key approach to
improving cancer survival rates (Cronin et al., 2018). Survival of cancers is dependent on
numerous factors namely: (1) stage of cancer (2) cancer type; (3) prior treatment strategy;(3)
level of fitness. In a study conducted by Lim et al. (2006), they found evidence of cancer survival
dependence on seasonality of diagnosis and sunlight exposure. Survival statistics are often used
for prognosis estimation and evaluation of treatment options (Cancer.net, 2018)
Surgical resection remains the main curative treatment approach for most cancers.
However, more than 60% of patients have unresectable cancer at the time of diagnoses such as
extra-regional lymph node metastasis and local invasion. Despite recent innovations in
chemotherapy strategy, the median survival for patients with skin cancer was approximately 113
months, for aerodigestive cancers was 70 months, and 107 months for patients with salivary
gland cancers. The survival rates for gastric cancer are among the worst of any cancer with a
3.1% five-year patient survival (Carey et al., 2019; Yang et al., 2011 and Brenner et al., 2009).
Data from National Cancer Intelligence Network (NCIN) showed that 70% of acute
lymphoblastic leukemia (ALL) patients will survive leukemia for five years or more after
diagnosis (Hoezler et al., 2016; National Cancer Intelligence Network, 2014; Tobias and
Hochhauser 2015; Wang et al.,2019).
Unresectable cancers are cancers that cannot be removed completely by surgery. Cancer
can be classified as unresectable for several reasons : (1) tumor location-a tumor may be
interconnected with vital blood vessel; (2) tumor size-too large to remove; (3) metastases-cancer
cells that have spread to other parts; (4) other medical condition that could increase the risk of
surgery-severe diabetes raises the risk of surgery to critical levels (Fabre et al., 2015; Imai et al.,
2016; Kato et al., 2015; Nitsche et al.,2015 and Yang et al., 2015)
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ALL is the second most common acute leukemia in the US and the American Cancer
Society ACS estimated that there will be ∼ 6000 new cases of ALL and ∼ 1500 deaths from

ALL in 2019 (Howlader et al., 2018; Terwilliger and Abdul-Hay, 2017). ALL is a malignancy
of hematopoietic stem cells that originates from B and T -cells. ALL pathogenesis involves
differentiation and abnormal growth of the lymphoid cells’ clonal population. Recent pediatric
studies have identified genetic syndromes that are predisposing to minor cases of ALL namely,
Bloom, Down and Nijmegen breakdown syndromes (Terwilliger and Abdul-Hay, 2017; Shah et
al., 2013; Bieloral et al.,2013; Chessells et al., 2001 and German 1997). Other factors include
exposure to Human Immunodeficiency Virus (HIV) (Geriniere et al., 1994), Epstein-Barr Virus
(EBV)(Seghal et al., 2010), pesticide and ionizing radiation(Spector et al.,2006). However, in
most cases, ALL appears as a new malignancy in previously healthy patients. ALL is often
driven by mutations, gene aneuploidy, and chromosomal translocation (Mohseni et al., 2018;
Hunger et al., 2015). Several genetic subsets of B-cell and T-cell ALL such as BCR-ABL1, MLL
rearrangements, Hypodiploid, iAMP21, ETV6-RUNX1, TCF3-HLF have to be found to play a
significant role in tumor development. Certain changes in leukemia cells’ genes or chromosomes
can affect prognosis and children tend to have a less favorable outcome if the leukemia cells
have a translocation between chromosomes 9 and 22 (Philadelphia chromosome); hypodiploidy
(fewer than 44 chromosomes)and complex karyotype while on the other hand patients tend to
have a better outlook if the leukemia cells have hyperdiploidy ( more than 50 chromosomes) and
a translocation between chromosome 12 and 21. Recent studies have shown that the risk for
developing ALL is highest in children younger than five years of age and that the risk declines
until the age of twenty-five and begins to rise again after fifty years of age. NCI SEER data
indicated that the median age at diagnosis is 16 years and the median age at death stood at 56
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years. The risk factors for ALL are radiation exposure, certain chemical exposure – benzene,
certain viral infections -HTLV1, certain genetic syndromes-Down, and Klinefelter syndromes,
age, race/ethnicity among other factors (Jain et al., 2016). Despite the high response rate to
chemotherapy, only approximately 35% of adult patients with acute lymphoblastic leukemia
attain long-term remission (Terwilliger and Abdul-Hay, 2017; Jabbour et al.,2015). The survival
of young patients with ALL has considerably improved in the 21st century, however, there is
insufficient data to determine if patients of all ethnic backgrounds have benefited equally (Pulte
et al., 2013)
Similarly, colorectal cancer the third most commonly diagnosed cancer in the US is
estimated to record over 50,000 deaths in 2019 (American Cancer Society,2020; Howlader et al.,
2016). The treatment for colorectal cancer has evolved in the last decade. FOLFOX and other
chemotherapy regimens remain the gold standard for therapy, however, the addition of known
epidermal growth factor receptor (EGFR) inhibitors have improved colorectal cancer outcomes
(Miyamoto et al.,2017). Fortunately, colorectal cancer has a 90% five-year survival rate if
detected early (American Cancer Society,2020). Gliomas, another lethal cancer are the most
common cranial tumors in adults representing 80% of malignant brain tumors. They originate
from glial tissue. Glioblastoma, the most prevalent glioma histology (∼45% of all gliomas) has
37.2%,5.1% and 2.6% survival rates for one-, five- and ten-year periods from diagnosis (Ostrom
et al.,2015). The minority of these tumors are caused by tuberous sclerosis and neurofibromatosis
and other Mendelian disorders. Recent studies indicate that isocitrate dehydrogenase mutation,
cytosine–phosphate–guanine island methylator phenotype and O⁶-methylguanine-DNA
methyltransferase methylation and other biomarkers significantly improved survival in glioma
(Ostrom et al., 2015). The Cancer Genome Atlas Research Network glioblastoma studies
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revealed recurrent alterations in the following pathways: (i) tumor protein 53 (TP53) signaling
(CDKN2A deletion, TP53 mutation, mouse double minute 1/4 [MDM1/MDM4] amplification);
(ii) retinoblastoma (RB) signaling (cyclin-dependent kinase inhibitor 2A/2C
[CDKN2A/CDKN2C] deletion, RB mutation, cluster of differentiation 4/6 [CD4/CD6]
amplification); and (iii) receptor tyrosine kinase signaling (phosphatase and tensin
homolog/neurofibromin 1/phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit
alpha [PTEN/NF1/PIK3CA] mutation, epidermal growth factor receptor/platelet-derived growth
factor receptor [EGFR/PDGFRA] amplification)( Cancer Genome Atlas Research Network,
2008).Glioblastomas are often genetically diagnosed as IDH-wildtype, IDH-mutant or
Glioblastoma with unknown IDH status. Noushmehr et al. (2010) and Mur et al. (2013) studies
found a substantial link between a genome-wide glioma cytosine–phosphate–guanine island
methylator phenotype (G-CIMP) and IDH mutations in all glioma subgroups.
Neuroblastoma is the most common extracranial solid tumor in infants and originates from the
neural crest element of the sympathetic nervous system (Stewart et al., 2016; Cheung and Dyer,
2013). It is a rare type of cancerous tumor and is the most common cancer in children accounting
for 6% of all cancers in infants. 90% of cases are diagnosed at age five (Stewart et al., 2016). It
occurs slightly more in males than females. Some of the risk factors associated with
neuroblastoma are age, heredity, and congenital anomalies. Biopsy, blood, and urine
catecholamine tests, imaging tests (x-rays, MRI, MIBG, CT scans), neurological exam and bone
marrow aspiration are among several tests and procedures done for the diagnosis of
neuroblastoma. Neuroblastoma’s spread description is known as staging. Staging helps clinicians
to determine the appropriate treatment option for a patient. Upon the diagnosis of neuroblastoma,
the tumor spread is assessed using the international neuroblastoma staging system committee
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(INSS) system. The INSS consists of six stages and are summarized as follows: (1) stage 1tumor can be excised completely by surgery; (2) stage 2A- the tumor is localized and cannot be
completely removed during surgery and surrounding lymph are not cancerous; (3) stage 2B- the
tumor is localized and may or may not be completely removed during surgery and the
surrounding lymph nodes are cancerous; (4) stage 3- the tumor cannot be excised with surgery,
often cancer has spread to surrounding lymph nodes; (5) stage 4- the tumor has metastasized to
distant lymph nodes, bones, liver, skin and other organs; and (6) stage 4S- the tumor is localized
(as in 1 and 2) and it has metastasized to the skin, liver and none in infants (Monclair et al.,
2009). INSS classification systems in combination with age at diagnosis, MYCN gene status,
chromosome 11q status, tumor cell ploidy, differentiated cell grade are used to determine the
clinical risk of a tumor and its response to therapy. A patient’s age and the INSS stage plays a
key role in the treatment approach for the disease. The treatment regimen for neuroblastoma
consists of three approaches namely surgery, radiation therapy, iodine 131-MIBG therapy
(treatment with radioactive iodine), chemotherapy and a combination of high-dose chemotherapy
and radiation therapy with stem cell transplants
In this study, we built a machine learning tree-based ensemble classification model for the
survival status of patients with selected unresectable cancers: acute lymphoblastic leukemia,
colorectal adenocarcinoma, glioblastoma, and neuroblastoma. Likewise, we implemented a
separate Cox-proportional hazard survival analysis for two unresectable pediatric cancers - acute
lymphoblastic leukemia and neuroblastoma.
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4.3

Methods

4.3.1 Survival Status Dataset
The dataset used in the study was retrieved from cBioPortal (www.cbioportal.org). The
dataset consists of clinical and genomic features such as age at diagnosis, ploidy, molecular
subtypes. In this study, we are primarily interested in ensemble classification of cancer survival
status of the following cancer sets namely pediatric acute lymphoblastic leukemia(ALL),
glioblastoma (GLIO), colorectal adenocarcinoma (COAD), pediatric neuroblastoma (P-NB) and
MSK-IMPACT clinical sequencing cohort - targeted tumor-sequencing of 10000 clinical cases.
Secondarily, we are interested in the survival analysis of ALL and P-NB due to the low median
age at diagnosis of pediatric acute lymphoblastic leukemia and pediatric neuroblastoma. Table 41 shows the total number of patients and samples used in this study.
Table 4-1. Total number of patients of selected cancer types and MSK_IMPACT combined
cancer type
Profiling Sample
(TARGET)

Total Number of Patients

Acute Lymphoid Leukemia (Pediatric)

1551

Glioblastoma

585

Colorectal Adenocarcinoma

594

Neuroblastoma (Pediatric)

1076

MSK_IMPACT cohort*

10336

*includes other cancer types
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Survival Status Data Preparation and Feature Selection
We carried out data management and exploratory analysis steps. In particular, we
implemented feature rescaling, missing value imputation and subsequent stepwise feature
selection. We assessed the pairwise correlations between the predictors as orthogonal covariates
are advantageous for building machine certain learning models. We also studied issues with
multicollinearity as they have the potential of causing overfitting in machine learning models
(Vatcheva et al., 2016; Atems and Bergtold, 2015, Zhang et al., 2018; Kroll and Song 2013)
Missing values imputation was handled by using the nearest neighbor and median values
approach depending on the data kind (categorical or numerical features). Other discrepancies
were handled using outlier detection techniques and min-max feature rescaling for data
normalization while regular expression and stepwise Akaike information criterion (stepAIC)
were used for feature extraction and feature selection respectively (Li et al., 2016; Zhang, 2016;
Paja et al., 2017). Since the main objective of this study is to build a predictive model for
survival status of acute lymphoblastic leukemia, glioblastoma, colorectal adenocarcinoma, and
neuroblastoma cancer, we carried out a quantitative and qualitative comparative analysis of the
overall survival status, sex, ethnicity/race, age at diagnosis, mutation count and survival event.
4.3.2 Proposed Models
4.3.2.1 Ensemble Classifiers
In this study, we used a comparative ensemble algorithms approach - extreme gradient
boosting (xgboost) and gradient boosting machine(gbm) for survival status classification as
described by Zheng et al, 2020; Chen and Guestrin,2016; Friedman,2001. We compared the
performance of the classifiers with that of deep neural networks as described by Telenti et al.,
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2018; Kalinin et al., 2018; Angermueller et al.2016. We adopted the D-CNN architecture used in
the Telenti et al., 2019 for this comparative study. Also, we investigated variable importance to
assess the most informative features in the survival ensemble models. To prevent overfitting of
the classifiers and account for the skewness in the distribution of the overall survival statusdeceased vs living, we oversampled the survival status using the synthetic minority oversampling technique -SMOTE (Zheng et al.,2019). SMOTE theory assumes that the feature space
of minority class instances is similar. We used F1-score, AUC, precision and recall metrics as
described by for our model evaluation as described by Zheng et al., 2020.
4.3.2.2 Cox Proportional Hazard Model
In the survival analysis of the pediatric neuroblastoma and glioblastoma, we used the cox
proportional hazards model as described by Wang and Albert, 2016; Meguid et al., 2010;
Xintong Chen, 2014 for semiparametric modeling the hazards ratio of the covariates.
4.4

Results and Discussion
Our initial exploratory analysis showed that MSK-IMPACT, neuroblastoma (P-NB),

glioblastoma (GLIO), colorectal adenocarcinoma (COAD) and acute lymphoid leukemia had
70.77 %, 62.72 %, 29.23%, 79.8% and 73.46% for the survival status distribution (Figure 4-1).
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Figure 4-1. Bar plot showing the percentage bar graph of survival status (living versus deceased)
of acute lymphoid leukemia (ALL), colorectal adenocarcinoma (COAD), glioblastoma (GLIO),
neuroblastoma (P-NB) and MSK-IMPACT cancer studies
In the EDA, all 4-cancer types have a higher survival rate except for glioblastoma, this
can be attributed to tumor location - glioblastoma is found in the brain’s cerebral hemisphere
which poses a challenge for chemotherapy and radiation. Age as a risk factor can also be
attributed to the high mortality rate among glioblastoma patients, the average age at diagnosis of
glioblastoma is sixty-four years and risk increases with an increase in age. Patients with
glioblastoma face major mortality, with approximately 13000 deaths per year in the US. Also, of
all 4 cancer types, colorectal had the highest survival rate of 79.8%. This aligns with NCI
statistics which puts the 5-year survival rate of colorectal cancer at 71% (SEER stage: regional)
and 90% (SEER stage: localized). Figure 2 shows the age at diagnosis of all four cancer types.
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Figure 4-2. Summary statistics of age at diagnosis (left to right): ALL, COAD, GLIO and P-NB

The multicollinearity dependence test of the features indicated that most of the features have
pairwise orthogonality except for sex (male vs female), tumor disease anatomic site (rectum vs
colon) and tumor type (colon vs rectal) with -0.99, -0.97, -0.78 and -0.91 correlation coefficients.
From the correlation matrix, diagnosis age, aneuploidy score, fraction genome altered, mutation
count, overall survival in months, race and other features are good for the model (Figure 4-3)
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Figure 4-3. Multicollinearity dependence test for some of the clinical (sex, age, race, tumor type,
overall survival in months) and genomic (fraction genome altered, aneuploidy score, mutation
count) predictors

4.4.1 Comparative Analysis of Ensemble Classification of Cancer Survival Status
The classifiers performed fairly well at classifying the survival status of ALL, GLIO, COAD, PNB and MSK- IMPACT models. The performance of the three classifiers (xgboost, GBM and DNN) employed in the survival status model was examined using metrics including
sensitivity(recall), specificity, precision, AUC and f-score (Table 4-2 and Figure 4.4A-E).
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The xgboost classifier performed best at classifying the survival status of the cancer types and
MSK-IMPACT except for the pediatric neuroblastoma model which recorded AUC and F-score
of 0.9447 and0.9268. In the ALL model, the xgboost classifier performed best with a sensitivity
score of 0.962, a precision score of 0.856, AUC score of 0.947 and an F score of 0.9058. The
recall value tells us that of all the ALL patients that survived, 96.12% of them were correctly
labeled as survived while the precision score tells us that of all the ALL patients that were
labeled as survivors, 85.59% of them survived. In the GLIO model, the recall and precision
values tell us that of all the diagnosed patients with glioblastoma that survived, 94.57% of them
were aptly labeled as survivors while of the diagnosed GLIO patients that were labeled as
survivors, 87% of them survived. Likewise, our COAD model indicated that of the diagnosed
patients that were labeled as survivors, 79.17% were correctly labeled as survivors. Of the
colorectal adenocarcinoma diagnosed patients that survived, 95% were correctly labeled.
In the pediatric neuroblastoma model, the GBM classifier outperformed both xgboost and the DNN classifiers – of the neuroblastoma survivors, 93.83% of them were correctly labeled as
survivors whereas of the neuroblastoma patients that were labeled as survivors, 91.57% survived.

A
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Figure 4-4. ROC/AUC model evaluation for survival status classification in ALL, GLIO, COAD,
P-NB and MSK-IMPACT data sets. The ROC plot of three classifiers – xgboost, GBM and DNN for ALL. A: In the ALL models, xgboost classifier performed best at discriminating survival
status (living v deceased) with an AUC score of 0.7355 whereas, the GBM with AUC 0.719
performed moderately well when compared with the D-NN with 0.6612 AUC score. B: In the
GLIO model, the xgboost was the best classifier with AUC score of 0.8448.C: Xgboost
classifier (0.9492) performed better at classifying survival status of COAD when compared with
D-NN (AUC:0.9068) and GBM (AUC: 0.9086) classifiers. D: Interestingly, in the P-NB model,
GBM (AUC: 0.9447) outperformed xgboost (AUC: 0.9171) and D-NN (AUC: 0.9078) at
classifying survival status of pediatric neuroblastoma E: MSK-IMPACT survival status – the
classifiers xgboost classifier with an AUC score of 0.7529 outperformed GBM and D-NN
respectively
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Table 4-2. Model evaluation result of the ensemble classifiers and deep neural network survival
status of selected unresectable cancer types
CANCER TYPE

ALL

GLIO

COAD

P-NB

MSK-IMPACT

METRIC

CLASSIFIERS
D-Neural Network

Xgboost

GBM

Sensitivity (Recall)

0.9333

0.9619

0.8667

Specificity

0.9448

0.9414

0.9517

Precision

0.8596

0.8559

0.8667

AUC

0.9418

0.9468

0.9291

F-score

0.8949

0.9058

0.8667

Sensitivity (Recall)

0.9674

0.9457

0.9348

Specificity

0.2917

0.4583

0.3333

Precision

0.8396

0.8700

0.8431

AUC

0.8276

0.8448

0.8103

F-score

0.8990

0.9063

0.8866

Sensitivity (Recall)

0.5417

0.7917

0.7083

Specificity

1.0000

0.9894

0.9574

Precision

1.0000

0.9500

0.8095

AUC

0.9086

0.9492

0.9068

F-score

0.7027

0.8637

0.7555

Sensitivity (Recall)

0.9012

0.9136

0.9383

Specificity

0.9118

0.9191

0.9485

Precision

0.8588

0.8706

0.9157

AUC

0.9078

0.9171

0.9447

F-score

0.8795

0.8915

0.9268

Sensitivity

0.3290

0.3246

0.2894

Specificity

0.9168

0.9295

0.9521

Precision

0.6298

0.6549

0.6667

AUC

0.7452

0.7529

0.7468

F-score

0.4322

0.4341

0.4036

4.4.2 Informative Features and Feature Importance of Survival Status Classification
Models
A combination of clinical and genomic features was used for the feature importance of all
five models. Due to various cancer types having different number of input features, we narrowed
the result of the feature features to the top-ten most informative features contributing to survival
status classification of ALL, GLIO, COAD, P-NB and MSK-IMPACT models (Figure 4-5A-E).
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Cell of tumor (T-cell) origin, age at diagnosis, cell of tumor (B-cell) origin, Congenital
abnormality, and the DNA Index were the most informative clinical features in the ALL model.
Whereas the ETV6-RUNX1, MLL_Rearranged, TCF3-HLF, Hypodiploid and iAMP21
molecular subtypes were the most informative genomic predictors.
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Figure 4-5. Top 10 most informative features contributing to classification of survival status of ALL, GLIO, COAD, P-NB and MSK-IMPACT
models. A: Clinical and genomic features such as cell of tumor origin, age at diagnosis, congenital abnormality, DNA index and Molecular
subtypes were the most informative predictors in the ALL model. B: Age at diagnosis, mutation count, fraction genome altered, therapy, gene
expression type, mutation type, sex, methylation status and number of samples per patients are the most informative predictors.
C: In the COAD model, age at diagnosis, mutation count, overall survival in month, fraction genome altered were among the top 10 informative
features. D: Clinical features including INSS stage, age at diagnosis, sex, race and risk group are predominantly the most informative predictor
when compared with ploidy feature. E: Overall survival in months, fraction genome altered, mutation count, smoking history were among the
most contributing features to the MSK-IMPACT model.
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Interestingly, in this ALL model, the clinical features were more informative than genomic
features (Figure 4-5A). In the GLIO model, age at diagnosis, mutation count, fraction genome
altered, therapy type, gene expression type, mutation type, sex, methylation status and number of
samples per patient contributed significantly to the model. Noteworthily, both clinical and
genomic predictors contributed almost at an equal ratio to the model (Figure 4-5B).
In the COAD model, clinical features including age at diagnosis, mutation count, overall
survival in months, tumor type, sex, tumor anatomic site, number of samples per patient and race
were the most predominant predictors whereas fraction genome altered was the only contributing
predictor in the model (Figure 4-5C). INSS_stage 2A, INSS_stage 3, INSS_stage 4S, age at
diagnosis, INSS stage 2B, Sex (male), ploidy, race, risk group and ploidy (hyperdiploid) were
the most statistical important features contributing to the P-NB model. Noteworthily, clinical
features were predominantly the most informative predictors whereas the genomic features
didn’t contribute significantly to the P-NB model (Figure 4-5D). In the MSK-IMPACT model,
overall survival (in months), sample coverage, fraction genome altered, mutation count, tumor
purity, DNA input, smoking history (unknown), sample type (primary), number of samples per
patient and smoking history (current smoker) were the most informative features in the model
(Figure 4-5E). Strikingly, age at diagnosis and sex were the prominent clinical features in ALL,
GLIO, COAD and P-NB models.
4.4.3 Survival Analysis
The median age at diagnosis for our acute lymphoblastic leukemia (ALL) and P-NB
sample sizes are 8 and 3 years respectively (Figure 4-6). The mean value of the fraction genome
altered (FGA) were 0.08 and 0.09 respectively even though a large number of the FGAs were
unknown.
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Figure 4-6. Summary statistics of age at diagnosis of ALL(left) and P-NB(right) with median
ages of 3 and 8 respectively.
In this study, we observed the representation of American Indian, Asian, black, Pacific Islander,
White (and White Hispanic) race/ ethnicity in the survival study (Figure 4-7). A significant
number of patients’ ethnic backgrounds were unreported. From our findings, children of
Caucasian descent had the highest reported cases of ALL and P-NB followed by children of
African descent. This confirms the findings of other studies such as Siegel et al., 2017 and
Friedrich et al., 2017 that the risk of ALL and P-NB is slightly higher in white and Hispanic
white children than in other races.
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Figure 4-7. Distribution of ethnicity and race of ALL and pediatric neuroblastoma P-NB. The
risk of ALL and neuroblastoma is slightly higher in white and Hispanic white children than in
other races.

The best Cox model for ALL showed that the covariates age at diagnosis, cell of tumor
origin (B and T-cells), congenital abnormality, DNA index, and MLL-rearranged molecular
subtype were significant predictors of survival (P < 0.05). However, the other covariates such as
molecular subtypes ETV6-RUNX1, hyperdiploid status 4 and 10 unknown, hyperdiploid without
trisomy of both chromosomes 4 and 10, hypodiploid, TCF3-HLF, TCF3-PBX1, iAMP21 were
not significant. The age at diagnosis with a hazard ratio of 1.03 shows that each additional year
of age at diagnosis is associated with a 3% increase in the risk of dying. Similarly, the cell of
tumor origin B-cell and T-cell with hazard ratios of 0.39 and 0.35 indicate that subjects with
these genetic variations have 61 and 64% decrease in the risk of dying compared to the baseline
group of B-cell precursor respectively. The congenital abnormality variable (No/Yes) with
hazard ratios of 0.59 and 8.30 indicate a decrease of 41% and an increase of 730% in the risk of
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dying compared to the baseline group with unknown congenital abnormality status. The
molecular subtype had 12 levels, unknown, BCR-ABL1, ETV6-RUNX1, Hyperdiploid with a
status of 4 and 10 unknown, Hyperdiploidy without trisomy of both chromosomes 4 and 10,
Hypodiploid, iAMP21, MLL-Rearranged, None of above, TCF3-HLF, TCF3-PBX1, Trisomy of
both chromosomes 4 and 10. Three of the categories, Hyperdiploidy without trisomy of both
chromosomes 4 and 10, iAMP21, None of above with hazard ratios of 0.70, 0.68 and 1.67 show
that the first two conditions decrease the hazard by 30 and 32% and the last increase the hazard
by 67% compared to the baseline group with unknown molecular subtype. The TCF3-PBX1
biomarker had levels unknown, negative and positive. The negative category with a hazard ratio
of 0.76 decreases the hazard by 24% compared to the baseline group of TCF3-PBX1 unknown.
The trisomy 4 and 10 feature had levels, unknown, negative and positive. The negative category
with a hazard ratio of 1.52 increases the hazard by 52% compared to the baseline group of
trisomy 4 and 10 unknown (Table 4-3).
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Table 4-3. Cox-proportional hazard results showing the effect size for pediatric acute
lymphoblastic leukemia
Cancer type

Covariates

Coef

Exp(Coef)

S.E

Wald Z

Pr(>|z|)

Age at diagnosis

0.03

1.03

0.005

6.66

2.75e-11

BCR_ABL1_status(negative)

-0.33

0.72

0.60

-0.54

0.59

BCR_ABL1_status(positive)

-0.27

0.76

0.68

-0.41

0.68

Cell of tumor origin (B-cell)

-0.93

0.39

0.07

-13.29

<2e-16

Cell of tumor origin (T-cell)

-1.04

0.35

0.08

-11.40

<2e-16

Congenital abnormality (no)

-0.53

0.59

0.18

-3.59

<0.001

Congenital abnormality (yes)

2.12

8.30

0.15

9.17

<0.001

MS = BCR-ABL1

0.18

1.19

0.36

0.49

0.63

MS = ETV6-RUNX1

0.01

1.00

0.11

0.01

0.99

MS =Hyperdiploid with status of 4 and 10 unknown

-0.18

0.83

0.25

-0.75

0.46

MS= Hyperdiploidy without trisomy of both chromosomes 4 and 10

-0.40

0.70

0.13

-2.73

0.01

MS=Hypodiploid

0.39

1.47

0.31

1.27

0.20

MS=iAMP21

0.51

1.67

0.26

1.96

0.05

MS=MLL-Rearranged

0.14

1.15

0.19

0.73

0.47

MS=None of above

-0.39

0.68

0.12

-3.19

0.001

MS=TCF3-HLF

0.60

1.83

0.58

-1.04

0.30

MS=TCF3-PBX1

0.15

1.17

0.29

0.52

0.60

MS=Trisomy of both chromosomes 4 and 10

0.15

1.16

0.17

0.89

0.37

TCF3_PBX1_status(negative)

-0.27

0.76

0.07

-3.92

<0.001

TCF3_PBX1_status (positive)

-0.29

0.75

0.28

-1.06

0.29

Trisomy 4 and 10 (negative)

0.42

1.52

0.07

5.23

<0.001

Trisomy 4 and 10 (positive)

0.23

1.25

0.13

1.73

0.08

ALL
(Pediatric)
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Similarly, the best Cox proportional hazards model for pediatric neuroblastoma showed
that the covariates INSS stages (2a,2b,3,4,4s) and hyperdiploid were significant (P < 0.05).
However, the covariate unknown ploidy was not significant with p values: 0.4884. The p-values
of INSS stages- 2,2b,3,4 and 4s diagnosis with a hazard ratio HR exp(coef) = 6.2115, 4.3297,
3.5981, 9.4593 and 0.6928 indicating a strong relationship between the sex, INSS stage and the
increased risk of mortality. Holding other covariates constant, a higher hyperdiploid is associated
with poor survival. Relatedly, sex =male (p-value: 0.02) with a HR = 0.8918, indicating a very
strong relationship between the male sex and increased risk of death. (Table 4-4).
Table 4-4. Cox-Proportional hazard results showing the effect size of pediatric neuroblastoma
Covariates

Coef

Exp(Coef)

S.E

Wald

Pr(>|z|)

Z

NB

Age at Diagnosis

-0.01

0.98

0.03

-0.83

0.40

INSS Stage 1

-0.84

0.44

0.19

-4.31

1.60e-05

INSS Stage 2a

-0.63

0.53

0.31

-1.98

0.04

INSS Stage 2b

0.03

1.02

0.25

0.10

0.92

INSS Stage 3

-0.04

0.96

0.19

-0.18

0.85

INSS Stage 4

-0.67

0.51

0.18

-3.76

0.0017

INSS Stage 4s

0.9916

2.6955

0.4747

2.09

0.0367

MYCN = Amplified

0.28

1.33

0.40

0.71

0.48

MYCN=Not Amplified

-0.11

0.90

0.11

-0.97

0.33

Ploidy_Diploid(DI =1)

-0.367

0.6928

0.0952

-3.86

0.0001

Ploidy = Hyperdiploid (DI >1)

0.87

2.39

0.21

4.14

3.42e-05

Sex=Male

-0.12

0.89

0.05

-2.33

0.02

Sex = Female

0.07

1.07

0.09

0.82

0.41
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5.1

Abstract

Background: Variants of uncertain significance remain a major challenge in contemporary
genetic variation screening methods. The advent of next-generation sequencing and other
bioinformatics resources have uncovered a significant number of variants of uncertain
significance which often hampers clinical decision-making.
Methods: We proposed an ensemble machine learning (ML) approach to classifying clinical
implication value of variants of unknown significance (VUS) using known mutation scores
(PolyPhen, SIFT and mutation assessor), allele frequency, mutation type (insertion, deletion,
frame shift), gnomAD among other features. Our machine learning models were evaluated using
precision, recall, f-measure and area under the curve metrics.
Result: Our results indicated that extreme gradient boosting and deep neural network classifiers
had the best performance in the VUS and biological effect classification models respectively.
Also, our results show that mutation predictive scores were the most informative features in the
clinical implication classification of the VUS.
Conclusion: The combination of ML model, genetic profiling and clinical information can
contribute significantly to our understanding and interpretation of genetically related cancers
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5.2

Introduction
Recent breakthroughs in next-generation sequencing (NGS) have played significant roles

in our understanding of human genetic variations. NGS technologies such as multigene panels,
whole-exome sequencing (WES), whole-genome sequencing (WGS) and genome-wide
association studies (GWAS) have paved the way for the synchronized analysis of many genes
and the generation of millions of short nucleic acid sequences in parallel (Oulas et al.,2019; Li et
al., 2017; Shendure and Ji, 2008; Bentley et al., 2008). Most variants identified by NGS in tumor
cells can be traced to carcinogenic complexity (Ding et al., 2012). NGS results acquired using
DNA or RNA extracted from tumor tissue often illustrate a convoluted molecular signature that
varies from that of normal tissue for any given patient (Li et al., 2017).
More recently, there is a consensus to incorporate NGS methodologies in clinical
diagnosis, prognosis, and overall patient counseling. This can be attributed to their costeffectiveness and accuracy as evidenced by the increase in FDA approval of NGS methodologies
(Green and Guyer 2011; Collins and Hamburg 2013). However, the overwhelming amount of
variants shown in each patient has called into question the interpretation of clinically significant
genetic variation (Yorczyk et al. 2015).
Cancer often arises from two to five mutations in various genes. These mutations are
complex and with a combinatorial effect commonly lead to tumor proliferation and cancer
progression (Levine et al.,2019). Oncogenes and tumor suppressor genes play prominent roles in
cancer progression. An oncogene arises from mutation of proto-oncogenes which often leads to
activation of uncontrolled cell growth. Most cancer-inducing mutations are acquired and activate
oncogenes by gene duplication and chromosomal rearrangements. Tumor suppressors normally
slow down cell division, regulate apoptosis and repair DNA errors. An anomaly in tumor
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suppression mechanisms can lead to abnormal cell growth. The major difference between a
tumor suppressor gene and an oncogene is that the former stems from the inactivation of protooncogenes while the latter causes cancer when activated. Studies have shown that most
oncogenes and tumor suppressor genes are acquired and not inherited (Mair et al., 2016;
Brognard et al., 2011).
Mutation can confer an enhanced activity on a protein or more often reduce the
functionality of a protein. Loss of function mutations in tumor-suppressor genes is often
oncogenic. Five main protein types are generally identified as tumor-suppressor gene encoders:
enzymes that participate in DNA repairs; proteins that promote apoptosis; intracellular proteins
that regulate progression through a specific stage of cell cycle; receptors for secreted hormones
that function to inhibit cell proliferation; and checkpoint proteins that stop the cell cycle if DNA
is damaged. A gain of function mutations is not as common as the loss of function. However,
activation of a proto-oncogene into an oncogene involves a gain of function mutation. For
example, ras gene a proto-oncogene that encodes an intracellular signal-transduction
protein; rasD gene, a ras mutant is an oncogene, which encodes oncoprotein provides an
uncontrolled growth-promoting signal (Lodish et al., 2000).
Clinical mutation screening (CMS) of cancer predisposition genes for the presence of the
mutation is often used for identifying patients with an elevated risk of cancer (Lindor et al.,
2012). The outcome from CMS is broadly categorized as pathogenic variation, benign mutation,
and variants of unknown significance (VUS).
Pathogenic mutation is genetic alterations with sufficient evidence to classify as capable of
causing disease. Well studied tumor suppressor genes such as APC, BRCA1, BRCA2, NF1,
TP53 have been linked with pathogenic (or likely pathogenic) variation (He et al. ,2016). For
110

example, the APC gene encodes a protein that is prominent in tumor suppression in WNT
signaling pathway. Studies have shown that the mutational loss of APC function contributes to
tumor proliferation and may lead to prostate cancer and colorectal cancer (Andres et al.,2018; He
et al. ,2016; Markowitz and Bertagnolli 2009: Chen et al., 2013). Benign tumors are generally
non-life threatening, although there are exceptions to this assumption. Benign tumors, for
example, may have fatal consequences in the brain. The skull is inadequately equipped to contain
tumor growth in the brain. Most benign tumors do not progress to malignancy. Benign cells
retain normal cell’s functionality. The majority of benign tumors have fewer mutations and these
mutations do not drive the more mutational proliferation (Wang et al., 2016). For example,
Rutkowski et al., 2000 showed that identifying defective cell types in NF1-associated
neurofibroma is important to understanding benign tumor mechanisms.
Variants of uncertain significance (VUS) are genetic mutations that have an unclear
impact on protein function (Alosi et al., 2017 and Easton et al., 2007). VUS are often amino acid
substitutions, intronic variants or small in-frame insertions or deletions. The actual effect of these
variants on gene function is unknown, this makes the assessment of their clinical significance
quite complex. About 50% of variants reported in well-studied genes such as p53, BRCA1 and
BRCA2 are designated as VUS based on the level of clinical evidence (Larson et al. 2014).
The number of VUS in the residual set remains substantial. The degree of pathogenicity is often
not trivial, considering that nearly fifty percent of the unique variants are novel, and cannot be
resolved using published literature and variant databases (Foley et al., 2015). Loss-of-function
variants represent a very small fraction of known variants. Other identified variants are missense
and synonymous variants in the exon, single nucleotide changes, or in-frame insertions or
deletions in intervening and intergenic regions (Mucaki et al., 2016). Several genetic
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susceptibility testing cancer patients often receive inconclusive and uncertain results that can be
attributed to inconsistent accuracy in silico protein-coding prediction tools which often becomes
challenging for clinical risk diagnosis. Variants of uncertain significance such as insertions
/deletions (INDELs) and single nucleotide polymorphisms (SNPs) cause dilemmas for clinicians
and uncertainty on how to advise patients.
In this study, we propose a xgboost machine learning (ML) approach to reclassify the clinical
significance value of VUS using a variety of prediction scores, mutation type and biological
effect namely: total number of nonsynonymous mutations in the sample, variant allele frequency
in the tumor sample, genome Aggregation Database (gnomAD), missense, fusion and in-frame
deletion) features as predictors. Our ML methodology (1) utilizes probability for clinical
significance class discrimination, (2) reclassifies a VUS’ clinical implication based on the
highest probability value, (3) Compares and evaluates the predictive power of various VUS
classifiers using precision, recall and ROC metrics, and (4) ranks the features based on their level
of informativeness .
5.3

Methods

In this study, we examined the prediction capability of xgboost model at reclassifying VUS
based on ACMG clinical values of cancer linked variants. The predictive performance of the
xgboost model was compared with multilayer perceptron and polynomial support vector
machines (SVM) models.
5.3.1 Genomic Variation Dataset
Open access CBioPortal and ClinVar databases were the primary sources of datasets (Cerami et
al., 2012; Gao et al., 2013; Landrum et al., 2017). A total of distinct 145 oncogenes and tumor
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suppressor genes (TSG) including EGFR, KRAS, BRAF, MYC, BRCA (1 and 2), JAK2,
IL2, and TP53 were used to aggregate the datasets for this study (Table 5-1). These cancer-linked
genes are the genes that have been well studied and have enough data for genomic analysis. The
dataset consisted of functionally validated 18548 tumor suppressor genes samples and 17590
oncogenic samples (Figure 5-2). A total of 43 functional and structural features including
missense variant, upstream gene variant, regulatory region variant, allele frequency, mutation
type, biological response(biotype) were used for the ML experiment. The classification models
were subsequently used for reclassification of VUS by considering data from 18 primary cancer
sites including liver, skin, ovary, prostate, kidney, lymphoid, stomach, bladder, cervix, pancreas,
thyroid, uterus, myeloid, bowel.
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A

B
Figure 5-1: Exploratory data analysis of the clinical implication of cancer-linked variations and
cancer gene types. (A) Summary distribution of clinical significance of genetic variants. (B)
Statistical distribution of cancer related genes- tumor suppressors and oncogenes
5.3.2 Clinical Significance Predictors: Feature Selection and Feature Importance
Analysis
The features selected used for VUS reclassification were obtained from cbioportal for
cancer genomics. The features used for the reclassification are broadly classified into (1)
Mutation type (splice region, missense, in-frame insertion, in-frame deletion, fusion); (2)
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Prediction scores (SIFT, PROVEAN, MutationAssessor, GERP, CADD, PolyPhen-2,
FATHMM, MutationTaster); (3) Sequence sample features (allele frequency, copy deletion,
copy gain, mutant in sample); (4) Biological effect impact (intron variant, splice donor variant, 3
prime UTR variants, missense variant, deleterious impact, chromosome location, cancer type,
loss of function, gain of function); and (5) Biotype/biological response (nonstop decay, misc
RNA, snoRNA, processed transcript, retained intron, CTCF binding site, processed pseudogene,
polymorphic pseudogene and translated processed pseudogene).
Clinical significance (risk level) was used as the response/target feature. Multiple
clinical and genetic evidence were combined to classify variants into 5 distinct risk levels: (1)
benign variants, (2) likely benign (VLB), (3) VUS, (4) likely pathogenic (VLP) and (5)
pathogenic variant (Table 5-2) (Richards et al., 2015; Karam et al., 2019). The benign variation
of clinical value includes polymorphic sequence variants which normally do not lead to disease
progression. A gene is considered polymorphic if more than one allele occupies the locus of a
gene within a population and its alleles must have a frequency of one percent or more in the
population. They are often found outside of genes and have neutral biological and function
effects. Polymorphic variation affects drug responses and contributes to disease susceptibility as
in the case of single nucleotide polymorphism. VLBs are alterations with significant evidence
against pathogenicity, they are not expected to play a role in disease progression. However,
additional evidence is usually needed to ascertain the clinical significance of these variants in
variation disease paradigm. VUSs are variations in genetic sequence for which association with
disease risk is unclear. VUS consists of a part of the gene that exhibits some alterations however
there is no sufficient molecular information to determine if its benign or a risk factor for cancer.
Over time, data is collected for reclassification of VUS. Generally, VUS are not used in clinical
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decision making, therefore other factors are considered along with VUS to make any clinical
diagnosis. VLPs have a high probability of pathogenicity. The identified variant is considered the
likely cause of the cancer but with a degree of uncertainty. The variants often result in impetuous
truncation in a gene where loss of function has been established as a mechanism of pathogenicity
for cancer development. Pathogenic variation involves alterations that increase susceptibility and
contribute to cancer development. Some pathogenic variants may not be wholly penetrant. Some
of these variants may not be adequately equipped to cause cancer on their own such as in the
case of recessive conditions. Usually, additional evidence has no impact on the classification of
the variants.
We computed 243 features for each sample in the datasets. The VUS data was queried
and set aside as unlabeled data. The remainder of the dataset (benign, VLB, VLP and pathogenic
samples) was resampled and partitioned into train and test sets (70-30 percent ratio) so as to
remove bias and prevent model overfitting. The train set consists of 70.80 % VLP, 28.39 %
MUT, 0.48 % VLB and 0.33 % POLY samples (Figure 5-2A). The training set was subjected to
outright removal of redundant features with high sparsity and recursive feature elimination
process, where one by one a feature is removed, and the model trained on the resulting data set.
If the accuracy of the model stays above a predefined threshold, the feature is removed
permanently, and the process is repeated. If removal of any feature increases the accuracy, the
threshold increases also. Single value elimination was used. We set a threshold of 0.001 less
accuracy to declare a feature important to prediction, resulting in a final data set of 43 features.
The test set contained 30% of the samples from the original data set, ensuring that the
distribution of variants of known significance were equivalent to that of the original data set
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A statistical test of dependence- Pearson’s correlation was done to assess the pairwise
relationships among the predictors. Ideally, orthogonal pairwise relationships are ideal and
desirable for building machine learning models. The goal of the multicollinearity check is to
identify pairwise relationship (high intercorrelations) that have potential of causing overfitting in
the machine learning models (P. Vatcheva et al., 2016; Atems and Bergtold, 2015, Kroll and
Song 2013). Data discrepancies- missing values imputation was handled by using nearest
neighbor and median values approach depending on the data kind (categorical or numerical
features).Other discrepancies were handled using outlier detection techniques and min-max
feature rescaling for data normalization while regular expression for feature extraction of string
features (Geng et al., 2018).
𝛽̂ ≡ 𝑎𝑟𝑔𝑚𝑖𝑛(∥ 𝑦 − 𝑋𝛽 ∥2 + 𝜆2 ∥ 𝛽 ∥2 + 𝜆1 ∥ 𝛽 ∥1

Where 𝛽̂ 𝑖𝑠 𝑝𝑒𝑛𝑎𝑙𝑖𝑧𝑒𝑑 𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟, ∥ 𝛽 ∥2 is the quadratic penalty term,
𝜆 → 𝑡𝑢𝑛𝑖𝑛𝑔 𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟, 𝛽 → 𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑠
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Table 5-1. List of oncogenes and tumor suppressors used for data collection and aggregation
Tumor Suppressors

Oncogenes

APC

IL2

TNFAIP3

ABL1

EVI1

MYC

ARHGEF12

JAK2

TP53

ABL2

EWSR1

MYCL1

ATM

MAP2K4

TSC1

AKT1

FEV

MYCN

BCL11B

MDM4

TSC2

AKT2

FGFR1

NCOA4

BLM

MEN1

VHL

ATF1

FGFR1OP

NKFB2

BMPR1A

MLH1

WRN

BCL11A

FGFR2

NRAS

BRCA1

MSH2

WT1

BCL2

FUS

NTRK1

BRCA2

NF1

BCL3

GOLGA5

NUP214

CARS

NF2

BCL6

GOPC

PAX8

CBFA2T3

NOTCH1

BCR

HMGA1

PDGFB

CDH1

NPM1

BRAF

HMGA2

PIK3CA

CDH11

NR4A3

CARD11

HRAS

PIM1

CDK6

NUP98

CBLB

IRF4

PLAG1

CDKN2C

PALB2

CBLC

JUN

PPARG

CEBPA

PML

CCND1

KIT

PTPN11

CHEK2

PTEN

CCND2

KRAS

RAF1

CREB1

RB1

CCND3

LCK

REL

CREBBP

RUNX1

CDX2

LMO2

RET

CYLD

SDHB

CTNNB1

MAF

ROS1

DDX5

SDHD

DDB2

MAFB

SMO

EXT1

SMARCA4

DDIT3

MAML2

SS18

EXT2

SMARCB1

DDX6

MDM2

TCL1A

FBXW7

SOCS1

DEK

MET

TET2

FH

STK11

EGFR

MITF

TFG

FLT3

SUFU

ELK4

MLL

TLX1

FOXP1

SUZ12

ERBB2

MPL

TPR

GPC3

SYK

ETV4

MYB

USP6

IDH1

TCF3

ETV6
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Table 5-2. The classification of genetic variants, based on the ACMG guidelines
Allelic Variants
clinical significance value
Polymorphism

Benign (POLY)

Variant-likely benign

Likely benign (VLB)

Uncertain significance

Variant of uncertain

Inconclusive

significance (VUS)

Variant-likely pathogenic

Likely pathogenic (VLP)

Somatic not response

Pathogenic (MUT)

Benign

VUS

Pathogenic

For comparison purposes, we examined the result of binary VUS classification. In the binary
models, the clinical significance values POLY and VLB were recategorized as “Benign” variants
while the VLP and MUT were redesignated as “pathogenic” variants.
5.3.3 Proposed Models: Extreme Gradient Boosting (xgboost)
In this experiment, we used xgboost as the primary classifier and compared its
performance with two other ML classifiers: polynomial support vector machines (poly-SVM)
and deep-neural network (multilayer perceptron) for VUS reclassification (Chen and Guestrin,
2016; Narasimhan and Agarwal 2017; Zhang et al., 2019; Agajanian et al., 2019 and
Sakellaropoulos et al., 2019). The choice of classifiers was chosen based on the following
criteria: speed and run time on train set and statistical- probabilistic interpretability of the
classification outcome. It is important to note that nominal features such as cancer gene type,
mutation type, and variation copy were processed for modeling using dummy variable (one-hot
encoding) technique. Dummy variables ensure a non-rank numerical representation of the
categorical features. xgboost, SVM-Poly, and NN classifiers were used for the 4 class and binary
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reclassification of the clinical implication of the VUS. To avoid the drawback of overfitting of
the classifiers and account for the skewness in the distribution of the benign-pathogenic binary
class, we oversampled the clinical implication using the synthetic minority over-sampling
technique -SMOTE (Zheng et al.,2015). For the model evaluation, we used the f-measure,
precision, recall, sensitivity, specificity and area under the curve (AUC) metrics as earlier
described in chapter 2. After evaluating the model performance, feature importance was done to
rank the most informative features used by the model for VUS reclassification.
5.4

Results and Discussion

5.4.1 Machine learning classification of cancer linked genes on variant datasets:
Prediction scores, Mutation type and Sequence sample features outperform
biological response predictors
We trained the SVM, xgboost and MLP/D-NN models by considering cbioportal cancerlinked variants datasets and using a set of diverse features including mutation type features;
biological response features; sequence sample features and prediction scores. In this analysis, we
examined the performance of the three classifiers and focused on identifying the five most
informative sets of features that contribute significantly to the VUS reclassification process
(Figure 5-3). In our prediction score sets, SIFT was the most informative feature that contributed
to the reclassification of VUS followed by PROVEAN, mutationassessor, Gerp and CADD.
Whereas in the mutation_type set, fusion was the most informative predictor followed by
missense, splice region, in-frame deletion and in-frame insertion (Figure 5-3A). In the sequence
sample features set, allele frequency was the most significant feature that contributed to the VUS
reclassification while copy gain, copy deletion, mutant in a sample and COSMIC occurrence
came in second, third, fourth and fifth place respectively. Whereas gain of function (bio_eff (G))
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and loss of function (biol_eff (L)) were the most prominent features in the biological
response/biological effect set (Figure 5-3A). Interestingly, upon the combination of the four
feature sets, allele frequency remained the most informative features in the ML reclassification
of the VUS (Figure 5-3B). In addition, missense variation that was less prominent among the
mutation_type set, is more informative upon the combination of all feature sets. Among the top
ten combined features, biological response feature sets, biological were cumulatively the least
informative features in the importance distribution in our model (Figure 5-2B)
5.4.2 Examination of Intercorrelation pairwise relationship among the prediction scores,
mutation type, sequence sample features and biological response feature sets.
A key rationale behind consideration of the intercorrelation among the features sets is to
examine the pairwise relationship among the predictors to identify and evaluate if there is
codependency among the prediction scores, mutation type, sequence sample features, and
biological features sets. Multicollinearity introduces bias and variance in a model and thereby
compromising the predictive power of a model. To check for feature codependency, we
computed and analyzed pairwise correlations between the feature sets with Pearson's pairwise
correlation coefficient (Figure 5-4). From our findings, SIFT had an inverse relationship with
MutationAssessor and PolyPhen scores -0.62 and -0.54. However, PolyPhen had a high positive
correlation with mutation assessor 0.48 (Figure 5-4). This confirms the complementary nature of
the mutation scores in predicting cancer pathogenicity. Overall, the correlation coefficient matrix
indicated that the combination of these features is orthogonal and therefore not prone to model
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overfitting

A

B
Figure 5-2: Feature importance analysis of xgboost ML model on cancer-linked dataset of
genomic variation showing the most informative features in VUS reclassification. (A) Feature
importance of prediction scores, mutation type, sequence sample and biological response feature
sets showing top-five most informative features. (B) Feature importance of all four feature sets
combination showing top ten most informative features
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Figure 5-3. Pearson’s pairwise correlation coefficients between the prediction scores, mutation
type, sequence sample and biological response features sets.

5.4.3 Comparative Analysis of Machine Learning Reclassification of Clinical Implication
of Variants of Uncertain Significance
We evaluated and compared the predictive performance of xgboost, SVM and D-NN/
MLP models using sensitivity(recall), specificity, precision and f-score metrics (Table 5-3).
The table showed that the xgboost model outperformed the SVM and D-NN/MLP models
( f-score = 0.92 ) in the reclassification of VUS clinical implication. Xgboost had a sensitivity of
0.9177 and a precision of 0.9311.
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Table 5-3. Comparative evaluation of classifiers for VUS clinical implication reclassification
Classifiers
Metric

SVM-POLY

Xgboost

Neural Network

Recall (Sensitivity)

0.8365

0.9177

0.8399

Precision

0.8411

0.9311

0.8147

F-score

0.8388

0.9244

0.8271

In the xgboost model, we recorded a recall, precision and f-measure scores of 0.9177,
0.9311 and 0.9244 respectively. This can be attributed to the relatively small sample size of the
benign and VLB class. On the other hand, xgboost had a weighted true positive rate of 91.77%
benign, VLB, VLP, and oncogenic(pathogenic) predictions respectively. In simpler terms, the
percentage of VUS mutations that were correctly classified as benign, VLB, VLP and pathogenic
while it had a true negative rate (specificity) of 84.25% (VLP) and 97.21%(pathogenic). Xgboost
recorded a precision of 0.935 and 0.9272 this means that a VUS was predicted to be likely
pathogenic (VLP) and pathogenic the predictions were correct 93.5% and 92.72% of the time
respectively. In the SVM-poly model, we had recall and precision scores of 0.8365 and 0.8411
respectively. Of the benign mutations, VLB, VLP and pathogenic, 83.65% were classified as
benign, VLP and pathogenic. Of the mutations classified as benign, VLP and pathogenic,
84.11% of them were correctly classified. In the deep neural network model, of the benign
mutations, VLB, VLP, and MUT 83.99% of them were classified as benign, VLB, VLP and
MUT while of the mutations classified as benign, VLB, VLP, and MUT 81.47% of them were
correctly classified. Overall, the xgboost model performed best with an F-score of 0.9244 when
compared with the SVM-poly and D-NN models.
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In the binary classification model, the xgboost classifier (with AUC: 0.7844) outperformed SVM
(AUC: 0.7365) and D-NN (AUC: 0.7404) classifiers at reclassifying VUS(Figure 5-5).
Evaluating the multiclass and binary models, we observed that the classifiers were better at
reclassifying VUS based on ACMG 4 point scale (benign, VLB, VLP and pathogenic) when
compared with the benign-pathogenic dichotomous class.

Figure 5-4: ROC/AUC plot for binary reclassification of VUS. Xgboost outperform SVM and DNN at reclassifying VUS
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6 Conclusion
Identification and characterization of cancer driving mutations remain a challenge in
understanding tumor progression. Several bioinformatic strategies have been developed to
examine the functional effects of variants that contribute to cancer. The incorporation of
biological context in predictive models means more robust and biologically relevant predictions.
In this dissertation, we leveraged ML predictions to (i) identify and classify cancer-linked
mutations, (ii) reclassify the clinical significance value of VUS and (iii) predict survival status of
selected unresectable cancers.
In the ML classification and functional analysis of cancer mutations study (Chapter 2),
we compared two cancer-specific machine learning classifiers (Logit vs. RF) for prediction of
driver mutations in cancer-associated genes that were validated on canonical data sets of
functionally validated mutations and applied to a large cancer genomics data set. We have found
that evolutionary-based features to be the most informative in machine learning predictions and
provide orthogonal information to the ensemble-based scores that dominate feature importance
ranking. By utilizing a comparative analysis with various structure–functional experiments and
multicenter mutational calling data from Pan-Cancer Atlas studies, we demonstrated that the
robustness of machine learning models that capture ∼90% of experimentally validated

mutational hotspots among predicted driver mutations. The results of this study have also
indicated that although the range of predicted driver mutations may be broader than the
experimentally validated group of drivers, some of the predicted “false positive” variants can
present viable candidates for further experimental testing and validation.
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In the integration of RF and D-CNN for classification of cancer driver mutations study
(chapter 3), we demonstrated that various ML approaches for prediction cancer driver mutations.
We explored the D-CNN model's capability of classifying cancer driver mutations directly from
raw nucleotide sequence information without depending on functional prediction and
evolutionary scores. The results further demonstrate that though D-CNN models can learn highlevel features from genomic information that has sufficiently high importance, accurate
classification of cancer mutation driver phenotype using exclusively nucleotide data is not a
practical approach.
In the survival status study (chapter 4), we used an xgboost model to predict the survival
status of five cancer studies and found that genomic features (molecular subtypes and ploidy)
and clinical features (age at diagnosis, race, sex) are critical components of survival status
classification. In the feature importance ranking analysis, age at diagnosis was a dominant
feature in ALL, COAD, GLIO and P-NB cancer studies. In the ALL Cox model, age at
diagnosis, cell tumor origin (T and B cells), TCF3_PBX1_status(negative), congenital
abnormality, MS= Hyperdiploidy without trisomy of both chromosomes 4 and 10 are statistically
significant features. Likewise, the INSS stage and ploidy are key predictors for examining the
survival rate of pediatric neuroblastoma. The results of this study suggest the further exploration
of genomic features will help in the understanding of survival indicators of cancer diseases.
In the VUS reclassification study (chapter 5), we have developed an intuitive machine
learning-based approach to classifying the clinical significance value of VUS. The major
findings of the present study are as follows (i) xgboost classifier does a decent job at
reclassifying clinical significance value of VUS with a precision score of 0.9177, recall score of
0.9311 and f-measure score of 0.9244 (ii) based on the analysis of our result, the three classifiers
132

reclassified most of the VUS as VLP,(iii) the classifiers are better at clinical significance
discrimination for ACMG four-tiered scheme than the binary models and (iv) mutation scores
and allele frequency are the most informative features need for VUS reclassification. Genomic
data remains the deciding factor in the clinical significance value of a variant -the level of
clinical evidence. To gather sufficient data, a collaboration between academia and industry
collaboration has to be fostered. Machine learning in combination with clinical information
about a patient (phenotype information and familial medical history) can help genetic counselors
and clinicians in understanding clinical interpretation of genetically related cancers.
Contribution of This Work to Cancer Studies
Previous works use clinical indicators in the diagnosis of cancer. However, we used the
combination of clinical and genomic features in the prediction and classification of cancerdriving mutations, VUS reclassification, and cancer survival classification. To evaluate the most
informative features in the cancer classifications mentioned earlier, we ranked features based on
their contribution to the models. This work has contributed to the identification and
characterization of cancer-driving genes, which are vital for early cancer detection. We have
demonstrated the robustness of the ML approach in the prediction and classification of cancerdriving mutations based on functional, evolutionary conservation, and integrated ensemble
scores. Our ML approach has highlighted the role of SNVs in cancer diagnosis. Additionally,
integration of ML approach with other computational strategies may improve the survival
outcomes of unresectable cancers.
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